Published in final edited form as:

J Alzheimers Dis Parkinsonism. ; 4: . doi:10.4172/2161-0460.1000137.

Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques

Mark H Sundman¹, Eric E Hall², and Nan-kuei Chen¹

¹Brain Imaging and Analysis Center, Duke University Medical Center, Durham, NC, USA

²Department of Exercise Science, Elon University, Elon, NC, USA

Abstract

Traumatic brain injuries (TBI) are induced by sudden acceleration-deceleration and/or rotational forces acting on the brain. Diffuse axonal injury (DAI) has been identified as one of the chief underlying causes of morbidity and mortality in head trauma incidents. DAIs refer to microscopic white matter (WM) injuries as a result of shearing forces that induce pathological and anatomical changes within the brain, which potentially contribute to significant impairments later in life. These microscopic injuries are often unidentifiable by the conventional computed tomography (CT) and magnetic resonance (MR) scans employed by emergency departments to initially assess head trauma patients and, as a result, TBIs are incredibly difficult to diagnose. The impairments associated with TBI may be caused by secondary mechanisms that are initiated at the moment of injury, but often have delayed clinical presentations that are difficult to assess due to the initial misdiagnosis. As a result, the true consequences of these head injuries may go unnoticed at the time of injury and for many years thereafter. The purpose of this review is to investigate these consequences of TBI and their potential link to neurodegenerative disease (ND). This review will summarize the current epidemiological findings, the pathological similarities, and new neuroimaging techniques that may help delineate the relationship between TBI and ND. Lastly, this review will discuss future directions and propose new methods to overcome the limitations that are currently impeding research progress. It is imperative that improved techniques are developed to adequately and retrospectively assess TBI history in patients that may have been previously undiagnosed in order to increase the validity and reliability across future epidemiological studies. The authors introduce a new surveillance tool (Retrospective Screening of Traumatic Brain Injury Questionnaire, RESTBI) to address this concern.

Keywords

TBI; head trauma; neurodegenerative disease; Alzheimer's disease (AD); Parkinson's disease (PD); Amyotrophic Lateral Sclerosis (ALS); Chronic Traumatic Encephalopathy (CTE); Magnetic Resonance Imaging; Diffusion Tensor Imaging; Resting State Functional Connectivity; Positron Emission Tomography (PET); retrospective TBI screening

Introduction

Even with its rising prevalence, there is a problematic lack of rigor in defining head trauma resulting in ambiguous and heterogeneous definitions throughout medical literature. However, TBI is generally defined as a closed head injury as a result of acceleration/deceleration forces and is separated into three categories: severe, moderate and mild. Severe TBI denotes head injuries that result in either permanent or an extended period of unconsciousness, amnesia, or death following a head injury and is quantitatively classified by a Glasgow Coma Score (GCS) of 3–8. In the middle of the spectrum, moderate TBI consists of a period of unconsciousness or amnesia ranging from 30 minutes to 24 hours with a GCS of 9–12. Mild TBI (mTBI) are generally recognized as head injuries that cause a brief state of altered consciousness that may result in up to 30 minutes of unconsciousness, but it is important to note that the majority of mTBIs do not result in loss of consciousness (LOC)^{1,2}. The transient and heterogeneous nature of mTBI symptoms make it exceedingly difficult to diagnose and, as a result, a large portion of these injuries go unrecognized. This is troubling considering that 80–90% of all head injuries are cases of mTBI^{1,2}. This most common form of TBI, mTBI, is often referred to as a concussion and these two terms will be used interchangeably throughout this review.

As it currently stands, TBI represents the leading cause of morbidity and mortality worldwide in individuals under the age of 45³ and it is still considered a growing epidemic with mounting evidence pointing towards increasingly dire consequences. The World Health Organization (WHO) reports an estimated 10 million people are affected annually by head injuries and predicts that TBIs will be the third largest contributor to the global burden of disease and mortality by 2020⁴. The WHO suspects that this increase in TBI prevalence is due to a growing number of automobile accidents, but there are many other potential exposures to TBI⁴. For example, the number of sports-related TBIs is increasing at a rapid pace with the most recent study estimating that 1.6–3.8 million occur each year in the United States alone⁵. This number is up from the previously reported estimate of 306,000 sport-related concussions in 1991⁶, which is a trend that is at least partly attributable to growing awareness of head injuries.

In addition to the human toll of these injuries, TBIs are affixed with a substantial economic burden. Without accounting for NDs later in life, the Center for Disease and Control (CDC) reports that mTBIs alone cost the USA \$17 billion annually, and that number jumps to \$57 billion when all TBIs are included⁷. Strikingly, this only accounts for hospitalized cases of TBI and does not recognize patients treated only in the ER, outpatient facilities, or those who omit medical care all together. These omissions are significant, especially when considering the mTBI frequently occurring in sports. According to one study, sports related concussions accounted for 20% (306,000) of the 1.5 million TBIs in the US⁵. Of those 306,000 patients, 55% received outpatient care and 34% received no medical attention^{5,8}. This means only 12% of these patients were hospitalized and, therefore, only 12% would be accounted for in the CDC's \$57 billion estimate for the economic toll for TBIs. The CDC also acknowledges that their incidence figures fail to illustrate the true extent of the prevalence of TBIs and the consequences associated with head injuries. They suggest that these numbers underestimate the amount of TBIs primarily due to the fact that there is still

no standard definition for a concussion and this lack of awareness contributes to a significant portion of TBIs going unreported^{6,7}.

A better understanding of the biomechanical forces causing TBIs may lead to a better understanding of their effects, enhanced protection, and potentially even aide in the diagnosis of head injuries. As such, researchers have increasingly focused on the biomechanical forces contributing to TBI. Both linear and angular/rotational acceleration forces contribute to TBIs, and they are classified as either focal or diffuse injuries depending on the mechanism of the injury. They are designated as focal injuries when the acceleration/deceleration forces cause impact between the brain and inner protrusions of the skull. Diffuse injuries, on the other hand, occur when the differential motion of the brain causes shearing and tearing of the axons, which results in diffuse axonal injuries (DAIs)⁹. Researchers are currently employing accelerometers in the helmets of athletes to obtain measurements for the various biomechanical forces that contribute to TBI in vivo. The Head Impact Telemetry System (HITS) is perhaps the most promising technology for this type of analysis and it incorporates multiple accelerometers within a standard football helmet that wirelessly communicate with a sideline computer in real time¹⁰. There are comparable findings for both college and high school (HS) athletes that have been examined using HITS. Diagnosed concussions in HS athletes resulted from impact forces with linear accelerations ranging from 74g–146g and angular accelerations from 5582–9515 rad/s/s¹¹. In college athletes, diagnosed concussions resulted from impact magnitudes of 60.5–168.7g¹². The measurements of impact forces resulting in concussions showed no correlation with symptom severity, postural stability, or neurocognitive performance following the injury¹². These findings have increased our understanding of the biomechanical properties behind TBIs, but the systems employed are currently unable to identify a “concussion threshold” that can be used to predict and diagnose TBIs.

In addition to investigating the causative biomechanical mechanisms of TBIs, a great deal of research is focused on the neuropathogenesis contributing to impairments following TBIs. As more is learned about the underlying pathophysiology of head injuries, there is greater evidence linking TBI with NDs including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and chronic traumatic encephalopathy (CTE). Recent estimates suggest that there are more than 25 million people suffering from dementia and NDs worldwide^{13,14}, a number that is sure to increase along with the demographic of our aging population. Worldwide, the proportion of people older than 60 is growing faster than any other age group. According to the WHO, this demographic of the population is expected to grow 223% between 1970 and 2025 totaling 1.2 billion people over the age of 60, which is expected to continue escalating to 2 billion people over 60 by the year 2050¹⁵. As a result of this growing demographic, it has been reported that the number of individuals affected by neurodegenerative diseases in the United States and Europe is expected to triple by the year 2050¹⁶ and it is reasonable to expect this trend to extend to the global population. In order to prevent the unprecedented financial, societal and emotional costs of these age related brain disorders, a better understanding of their risk factors is compulsory to limit their prevalence.

These neurodegenerative disorders are all multifactorial diseases with unknown etiologies, but it is hypothesized that TBIs are a primary risk factor for each due to the similar nature of their pathologies^{17–20}. There have been a number of epidemiological studies done attempting to quantify the relationship between TBI and these neurodegenerative diseases, but they yield conflicting and inconclusive results.

Dementia and Alzheimer's Disease

Epidemiology

Every 70 seconds, somebody in America develops dementia, which results in 450,000 new cases each year²¹. Dementia is an overarching term involved in a number of disease processes, but AD represents the most common form of dementia in the elderly. It is a disease characterized by the progressive loss of memory and cognitive capacity significant enough to interfere with quality of life. Mild cognitive impairment (MCI) often precedes full-blown AD and can be conceptualized as a transitional state between normal cognitive aging and dementia. Previous research indicates individuals with MCI progress to AD at a rate of 10–15% per year compared to just 1–2% of the general population^{22,23}. Therefore, MCI can be used to identify populations who are at risk of developing AD. One compelling study that utilized questionnaires from 2552 retired professional football studies suggests that head trauma may be associated with impaired cognition, thus increasing the risk for dementia. These athletes, who have had extensive exposure to repetitive head injuries, displayed a progressive decline in mental health functioning and higher rates of memory impairments and cognitive decline that are representative of MCI. Findings from this study also demonstrate a dose-response relationship between diagnosed concussions and an increased lifetime burden, as players reporting three or more concussions had a five-fold increase in prevalence of MCI²³. However, no correlation was observed between concussion history and AD²³. Studies like this have prompted researchers to further examine the relationship between TBIs and neurodegenerative disease.

Of the various neurodegenerative diseases, there is the strongest evidence suggesting a link between head trauma and AD. A meta-analysis of 15 case-control studies found that individuals with a history of TBI were 60% more likely to develop AD compared with others²⁴. Within a population of AD patients, it has also been reported that history of TBI accelerates the onset of AD^{25,26}. However, there are also studies that refute this relationship reporting no increased risk of AD for those who have sustained head trauma at some point in their lifetime^{27,28}. It is also likely that the effects of TBI may vary between individuals as some research indicates that head trauma is only a risk factor for AD when the individual is a carrier of certain alleles, most notably the e4 allele of Apolipoprotein E (APOE)^{29,30}. It is worth noting that APOE is a plasma lipoprotein primarily responsible for transporting lipids through the CNS that plays a vital role in synaptogenesis along with the maintaining, repairing, and remodeling of neuronal tissue³¹. One study in particular reports that carriers of this APOE e4 allele with history of TBI have a 10-fold increased risk of AD while non-carriers of this allele with TBI history had no increased risk of dementia³⁰. In comparison, possessing the APOE e4 allele with no history of head trauma indicated a two fold increase risk of AD³⁰. Perhaps the most telling finding comes from one of the few prospective

studies that examined a population of World War II veterans and reports that TBIs significantly increase the risk of developing AD later in life³².

Pathology

The major pathological hallmarks in the brain of AD patients are neuronal loss, synaptic dysfunction³³, and plaque deposition, which primarily consists of Amyloid- β ($A\beta$) peptide and neurofibrillary tangles (NFTs) composed of phosphorylated tau protein²¹. $A\beta$ aggregation is widely regarded as the chief component in the pathogenesis of AD³⁴. $A\beta$ deposition primarily occurs in cortical regions responsible for memory and learning as well as in the small blood vessels of the meninges and cerebral cortex²¹. Oxidative stress and mitochondrial dysfunction are also key contributors to the pathological cascade leading to AD³⁵.

The first major indication of similar underlying pathologies between TBI and neurodegenerative disease was observed when researchers discovered $A\beta$ plaque in the brains of up to 30% of patients who died acutely following TBI³⁶. Notably, these $A\beta$ plaques were also found in children following fatal TBI indicating that the plaque was not present due to standard AD progression in undiagnosed individuals before the TBI occurred. Tau pathology of NFTs, another key component of AD's pathogenic cascade, has also been observed following head trauma. Though it is more commonly observed in cases of repetitive head trauma, it has been observed as a chronic effect following a single TBI³⁷. Increases in neuronal tau accumulation following exposure to head trauma was initially observed in rats³⁸, but this finding was later observed in humans as well. This increase of intraneuronal tau pathology is also observed in younger patients following acute head injury, suggesting it is not solely attributable to aging³⁹.

Researchers have attempted to delineate the biological processes by which the neuropathology following TBI may elicit a pathogenic cascade contributing to the progression of AD and other NDs. The chief event suspected of triggering this cascade appears to be the microstructural white matter injuries, known as DAIs, that often occur in head trauma. DAIs cause damage and swelling to the axonal cytoskeleton, which results in impaired axoplasmic transport⁴⁰. This impaired axonal transport leads to the abnormal production and accumulation of toxic proteins, peptides, and their aggregates immediately following the trauma^{40,41}. In relation to AD, amyloid precursor protein (APP) is one of the key proteins affected by this impaired axonal transport, leading to a rapid and considerable accumulation of APP in the damaged axons⁴². APP is the substrate that is later cleaved to form $A\beta$, so this event yields ample substrate readily available for intraaxonal $A\beta$ production^{40,42}. This axonal $A\beta$ accumulation is then released and deposited in the tissue parenchyma as $A\beta$ plaques that are characteristic of AD pathology. It appears that this process occurs spontaneously in aging adults as part of the normal progression of AD, but these DAIs significantly accelerate the process thus predisposing individuals to greater risk of neurodegenerative disease^{40,41}. Notably, this axonal degeneration and $A\beta$ accumulation via increased APP has been identified as a progressive long term effect that persists years following the initial head injury⁴³. This process is likely influenced by various metabolic and genetic factors.

Intraaxonal production of NFTs, another hallmark of AD and other neurodegenerative diseases, has also been identified as a consequence of TBI. As observed with A β accumulation, the primary mechanism of post-traumatic NFT aggregation is impaired axonal transport following DAI⁴⁰. The accumulation of NFT following head trauma is well established in both animal and human models, and it has been shown to accumulate at a relatively slower rate than APP with the first signs of NFT detected at 6 hours after the injury^{40,44}. While A β accumulation has been observed as an acute effect following TBI in humans suffering fatal injuries, the accumulation of NFT has yet to be reported as acute response to a single head injury in humans. However, greater aggregate levels of NFT has been observed as a long term effect in TBI patients surviving at least one year following a single head injury compared to age matched controls³⁷. This increase in intraaxonal NFT accumulation, even in individuals with history of only a single traumatic event, may be a significant risk factor for developing neurodegenerative disease later in life.

Similarly, this impaired axonal transport following DAI can also result in abnormal α -synuclein accumulation. The intraaxonal α -synuclein accumulation resulting from DAIs are typically the nitrated and conformationally modified forms that are representative of synucleinopathies⁴⁰. Additionally, the oxidative stress following TBI may augment the accumulation of α -synuclein or play a role in stabilizing the aggregated forms of α -synuclein^{40-41,45}. This augmented α -synuclein accumulation may contribute to dementia with Lewy bodies, which is a form of dementia distinct from AD⁴¹.

Neuroimaging

Previous studies have employed conventional MR techniques utilizing T₁ and T₂ weighted imaging to obtain structural and anatomical images of the brain. These studies aim to use volumetric and voxel-based morphometry (VBM), which is well established as a tool to observe cerebral atrophy at a macroscopic level, specifically by measuring the changes in gray matter density across disease states⁴⁶. Cortical atrophy has been observed in AD patients by studies reporting significantly reduced gray matter densities across various regions of the brain, specifically in the medial temporal lobe structures including the hippocampus, amygdala, and uncus^{47,48}. In addition to whole brain atrophy, ventricle to brain ratio (VBR) is a well established global measure of brain integrity^{49,50}. When cerebral atrophy occurs, the loss in total brain volume (TBV) is accompanied by increased ventricular volume, thus increasing the VBR, which is indicative of neurodegeneration and AD⁵¹. These findings compelled researchers to develop a hypothesis regarding the pathogenesis of NDs centered on initial brain reserve⁵². This hypothesis proposes that the greater one's brain reserve is, the more they will be able to compensate for the normal pathological changes of aging to resist the clinical symptoms and functional impairments of ND. Thus, this theory postulates that populations with decreased brain volumes and gray matter density will be at greater risk of developing NDs later in life. In addition to the findings above which seem to support this hypothesis, a study specifically investigating the initial brain reserve hypothesis indicated that those with less brain volume are at greater risk for developing dementia later in life⁵³.

Parallel findings are observed in studies investigating the cortical atrophy that occurs following TBI⁵⁴. One study found that significant brain atrophy is already observed just 11 months after a mild/moderate TBI and they report that the atrophy was even more pronounced in patients who experienced loss of consciousness (LOC) at time of injury⁵⁵. The evidence of cerebral atrophy in TBI patients using VBM is further supported by a post-mortem study examining the brain matter of moderate-severe TBI patients who survived several months to years in a severely disabled or vegetative state⁵⁶. This study reports a significant reduction in both the brain mass and volume compared to controls in relatively young patients, who were an average of 44 years of age at the time of injury⁵⁶. A longitudinal study using VBR measurements to assess the global cerebral atrophy of mild/moderate TBI patients at different time points following their injury indicates progressive and chronic cortical damage that is comparable to AD patients⁵⁷. The findings indicate that the most rapid increase in VBR occurs approximately 3 weeks after injury, but perhaps more importantly, they found that VBR continues to progressively increase beyond two years after the injury occurred⁵⁷. In addition to the parallel findings of global brain atrophy, it is also reported that regional atrophy occurs in both AD and TBI that is specific to the same regions and structures of the brain such as the hippocampus⁵⁸. It is possible that these alterations in VBM and gray matter density cause deleterious effects, especially when considering the aforementioned initial brain reserve hypothesis. It appears that head injuries deplete this initial brain reserve, which in turn could significantly predispose TBI patients to future risk of neurodegenerative disease as they lack the same capacity to overcome the neurological impairments experienced in normal aging.

In recent years, tremendous advancements have been made in developing new neuroimaging modalities that allow a more detailed look at the microstructural connectivity of the brain. This may provide key insights to understanding and quantifying pathology resulting from DAIs in specific regions of interest (ROIs) that are not able to be assessed using conventional MR and CT methods. Diffusion Tensor Imaging (DTI) is a non-invasive MRI method that is sensitive to the microscopic alterations of neuronal tissue, specifically occurring in the WM of the brain. DTI is able to provide this detailed information regarding the microstructure of the brain by measuring the diffusivity properties of water. For example, movement of water in CSF is unrestricted and, therefore, it is free to diffuse in all directions (isotropic). WM, however, is encapsulated by myelin sheaths, neurofilaments, microtubules, and axonal membranes that restrict diffusion to the direction that the axons are lying (anisotropic). The two primary indexes of DTI measure the directionality and magnitude of the diffusion properties; Fractional Anisotropy (FA) measures the directionality and Mean Diffusivity (MD) measures the magnitude of diffusion. Reduced FA and increased MD values are indicative of structural impairments within the white matter as it reflects myelin/axonal damage.

Studies using DTI to investigate WM structural integrity in AD patients yield compelling results. Many have found white matter abnormalities, as marked by a reduction in FA values, in multiple fiber tracts involving the uncinate, superior longitudinal fasciculus (SLF), inferior longitudinal fasciculus (ILF), fornix, cingulum, hippocampus, and corpus collosum (CC)^{59–65}. Though there are also a handful of studies that fail to observe a significant reduction in FA values⁶⁶, a recent meta-analyses of 41 studies on DTI in AD patients reports

significant reduction of FA values for 11 of 13 ROIs compared to healthy controls⁶⁷. This same meta-analysis also reports increased MD values indicative of microstructural damage in all 9 of the ROIs including the CC, posterior cingulum, uncinate fasciculus, and the hippocampus.

This same DTI modality has also been applied to TBI populations to observe the acute and chronic microstructural abnormalities resulting from head trauma. According to the findings of abnormal FA and MD values, the overwhelming trend indicates that chronic impairments to WM structural integrity occur as a result of TBI in areas comparable to the abnormalities reported in AD patients^{68–77}. It is also worth noting that several studies report a significant trend between severity of the TBI⁷⁸ and the number of TBIs⁷² with the extent of WM structural damage. Of particular interest, some of these DTI studies reporting significant WM impairments also note that the conventional CT and MR scans at time of injury were normal⁶⁹. This indicates that there is often structural damage occurring as a direct result of head trauma that is undetected at the time of injury by conventional measures. Several studies also report that WM integrity is correlated with measures of executive function and reaction time^{75,76} and microstructural WM abnormalities can be predictive of negative outcomes following TBI⁷⁹. The findings are less consistent in studies that assess the acute changes in WM integrity following TBI (within 1 month). Several of these acute studies also observed WM abnormalities in key regions like the CC and fornix^{78,80–82}, but others found no difference compared to controls^{83,84}. Interestingly, and perhaps surprisingly, several acute studies have found that FA values are increased and MD values are reduced in acute TBI patients that are still symptomatic^{85–86}. These findings raise new questions regarding the recovery mechanisms and progressive changes in the brain as a result of head trauma. It is possible that this unexpected finding is the result of an immediate response mechanism that is later followed by decreasing FA values as the brain recovers, but a longitudinal study examining microstructural alterations following TBI is necessary to better understand these findings.

Another new, non-invasive imaging modality utilizes the blood oxygen level dependent (BOLD) measures that are typically used to obtain task based functional MRI (fMRI) data. Researchers are beginning to measure these BOLD fluctuations in the brain during its resting state, which represent the amount of intrinsic activity synchronization across the entire brain. These resting state fMRI measures are thought to represent what has been termed functional connectivity^{87,88}. This may provide a valuable data resource for delineating the neural functional architecture of humans, and, coupled with DTI, may provide insight to the intrinsic connectivity networks (ICN) of the brain⁸⁹. The majority of the brain's resources are expended during rest to maintain homeostasis, so measures of resting state networks (RSN) can provide key insight into the overall health of the brain at rest⁹⁰. Another benefit of using resting state values is the fact that it does not involve the subject's engagement in cognitive tasks so it can be widely applied to different patient populations, even anesthetized individuals^{90,91}. However, attempting to define a baseline state in the brain, arguably our most complex system, poses a difficult challenge⁹². As researchers are attempting to optimize results from resting state functional connectivity fMRI (fcMRI) studies, they are using different methods (i.e., Seed-Based Correlation Analysis, Independent Component Analysis, Frequency Domain Analysis, and various

group level analysis approaches) to analyze the data leading to increased heterogeneity between labs⁸⁹. Additionally, there are a number of other factors such as compensatory effects and effects of medications that may influence functional connectivity in ways that are not entirely understood⁹³. These varying methods of analysis and relatively unknown effects make the findings from these studies difficult to interpret and compare, but they still yield compelling results.

fcMRI techniques have been applied to AD populations in an attempt to identify ICNs involved in the progression of the disease. The network receiving the most attention in these fcMRI studies is the default mode network (DMN), which is a network of brain regions that is active during rest and typically deactivates during performance of a task⁹². The primary regions of the DMN include the medial prefrontal cortex, posterior cingulate cortex (PCC), lateral temporal cortex, angular gyrus, and parahippocampal gyrus^{94,95}. fcMRI studies examining AD patients reveal disruptions to the DMN through several different methods of analysis^{96–100}. The link between DMN disruptions and AD is strong enough to compel some researchers to believe that activation patterns within the DMN directly explain, or potentially even cause, the pathology of AD⁹⁴. This finding has led researchers to develop what they call the “metabolism hypothesis”. This hypothesis postulates that the continuous activity of the DMN augments a metabolism dependent cascade that is conducive to the formation of AD pathology, primarily A β deposition⁹⁴. Mappings of A β plaques show a distribution that is strikingly similar to the anatomical regions comprising the DMN^{101,102}, indicating that hyperactivity of the DMN may increase risk of AD.

A longitudinal fcMRI study investigating the progression of AD supports this metabolism hypothesis. It reports increased DMN activity in the early stages of AD and in healthy controls, but the DMN quickly deteriorates in AD patients and continues to diminish as the disease progresses¹⁰³. This could support the metabolism hypothesis because the increased metabolism, indicated by hyperactive DMN, leading up to AD results in increased deposition of A β plaques, which in turn intensifies the pathogenic cascade of AD. Another possible explanation for this finding is that the increased DMN in early cases of AD and healthy controls could be a result of healthy aging successfully compensating for diminished cognitive capacity, but their AD symptoms rapidly progress once patients are no longer able to maintain these compensatory effects¹⁰³.

fcMRI studies investigating the effects of TBI examine a number of different ICNs, but for the sake of comparison to these AD findings this section will focus on the DMN. Two studies investigating the chronic effects of TBI on the DMN (>6 months) report an overall increase in DMN as a result of TBIs^{103,104}. It is also reported that this increased DMN activity is correlated with impairments of sustained attention, which is further supported by the finding of increased deactivation of DMN during tasks¹⁰⁴. Other studies report diminished functional connectivity in the DMN within 6 months of sustaining a mild TBI^{106,107}. More longitudinal work needs to be done, but it is possible that the functional connectivity of the DMN decreases immediately following TBI and increases during later stages of recovery as a compensatory effect. This is supported by research incorporating DTI to investigate ICNs, which reports reduced signaling efficiency in defective axonal bundles¹⁰⁸. These defective axonal bundles, which are present in TBI patients as a result of

DAI, eventually lead to inefficient networks that are required to work harder and overcompensate for the structural impairments in order to complete the same tasks¹⁰⁸. This finding could potentially explain the heightened risk factor for neurodegenerative diseases later in life according to the metabolism hypothesis proposed by Buckner and colleagues⁹⁴.

Positron Emission Tomography (PET) and single positron emission computed-tomography (SPECT) provide unique insight to alterations of the brain's metabolism across different disease states. PET assesses cerebral metabolic activity, most commonly the metabolism of glucose by using the tracer ¹⁸F-2-fluoro-2-deoxyglucose (FDG)¹⁰⁹. Uptake of FDG in the brain indicates local glucose consumption providing energy to maintain ion gradients and synthesize neurotransmitters, which closely corresponds to levels of neuronal function¹¹⁰. Accordingly, a decline in glucose consumption is indicative of synaptic dysfunction and neuronal degeneration, which is commonly observed in neurodegenerative diseases¹⁰⁹. SPECT also employs tracers to assess biological activity in specific regions of the brain, but does so through measuring levels of perfusion. PET exhibits significantly greater sensitivity and spatial accuracy, but SPECT offers extended time windows to observe biological processes over the course of hours or days¹¹¹.

When these neuroenergetic modalities are applied to AD patients, the most consistently reported findings are resting-state temporo-parietal hypometabolism in PET scans and temporo-parietal hypoperfusion in SPECT imaging^{112–118}. Significantly reduced metabolism in the temporo-parietal cortex has also been observed longitudinally as AD progresses, which was further supported by one study that post-mortemly confirmed groupings for cognitively healthy and AD patients^{114,115}. Reduced cerebral metabolic rates for glucose (CMRgl) in AD patients are also commonly observed in the PCC, precuneus, thalamus, mammillary bodies, hippocampus and frontal cortex^{114,116,118–120}. The implication of suppressed CMRgl in the PCC relates to the fMRI studies mentioned above since the PCC is a central node of the DMN. Other PET scans employ compounds capable of penetrating the blood-brain barrier such as the Pittsburgh Compound-B (PiB) with a high affinity for amyloid-B, which can effectively track A β aggregation in vivo¹⁰¹. Utilizing the PiB compound to map A β pathology via PET has been supported by strong correlations to post-mortem A β pathology findings¹²¹. In both controls and AD patients, research has shown a distinct relationship with higher levels of metabolism correlated with greater levels of A β pathology, specifically in the DMN^{101,122}. This also supports Buckner's metabolism hypothesis indicating that hyperactivation of DMN may be a risk factor for AD later in life⁹⁴.

There is surprisingly limited data available to examine PET measures of CMRgl following TBI considering PET lends itself well to the many clinical issues emerging following incidents of head trauma. Additionally, the variable nature of TBIs makes this a difficult disease population to study because factors like severity, frequency, and time since injury are likely to influence CMRgl results. From the limited data available, it appears that there is an initial phase of increased CMRgl^{123,124} followed by a period of reduced CMRgl and hypoglycolysis following TBI^{124–126}. One study provided additional longitudinal insight by scanning patients three times during hyperacute (<5 days), acute (5–28 days), and chronic (1–6 month) recovery. They report a triphasic pattern with initial hyperglycolysis, followed

by reduced CMRgl that later increases and recovers to normal levels by 6 months¹²³. For the most part, these FDG PET studies only report findings of global CMRgl. One study reported regional measures, which indicated reduced CMRgl in bilateral frontal lobes, temporal lobes, thalamus, and right cerebellum up to 6 months following TBI. Additional studies are needed to gain insight into the true chronic consequences of TBI on CMRgl. The observation of a triphasic pattern for metabolic response following TBI relates well to observations in the aforementioned fMRI studies. However, these PET studies only report CMRgl up to six months post-injury, but the trend at this time point is an increase in CMRgl from previously reduced levels¹²³. If the CMRgl continues to increase in the years following TBI, there may be serious implications involving the DMN and altered resting state functional connectivity that may implicate Buckner's metabolism hypothesis.

Another interesting PET study investigated the neuroinflammatory effects of TBI in a group of patients suffering from chronic symptoms from TBI. This PET study was able to measure inflammation by utilizing a different tracer, ligand [11C](R)PK11195 (PK), which is previously known to indicate activated microglia and, thus, is a sign of inflammation¹²⁷. Within this study's population, the mean time since injury was 6.2 years with the most remote TBI occurring 17 years earlier. The PET scan indicated that all TBI patients had increased levels of persistent inflammation in subcortical regions like the thalamus and putamen and, though there is no correlation between time since injury and inflammation, the greatest PK uptake indicating greatest inflammation was observed for the participant whose injury was the most remote in time at 17 years¹²⁷. This finding of perpetual neuroinflammatory mechanisms in the brain following TBI is substantiated by an immunohistochemistry study reporting increases in activated microglia and phagocytic macrophages in TBI patients for up to 18 years following a single head injury¹²⁸. Neuroinflammatory responses like this are increasingly acknowledged as a chronic feature of multiple neurodegenerative diseases^{129–134}.

PET scans may also have the potential to examine the level of tau pathology developing in the brain following TBI by utilizing 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile (FDDNP). One recent study employed FDDNP PET scans on retired NFL players who have a history of repetitive exposure to TBI to see if there were any significant differences in tau compared to the general population¹³⁵. The research indicates that the group of retired NFL players had significantly greater levels of tau pathology than healthy controls in the amygdala and all subcortical ROIs including caudate, putamen, thalamus, subthalamus, midbrain and cerebellar white matter¹³⁵. Previously, tau pathology, a hallmark of AD, was found to exist in the brains of athletes with CTE as discovered post-mortemly by McKee and colleagues, but this offers an approach to investigate this facet of the pathogenesis in vivo¹³⁶. This is yet another pathway and neuroimaging modality that has the potential to be investigated as a means of in vivo identification of neurodegeneration in at risk populations.

Parkinson's Disease

Epidemiology

PD is the second most common neurodegenerative disorder. The clinical manifestation of PD is characterized by resting tremor, rigidity, bradykinesia, and postural/balance impairments. In addition to these motor impairments, a wide variety of non-motor comorbidity symptoms are observed in PD patients including depression, cognitive impairments and olfaction dysfunction¹³⁷. Depression is perhaps the most common non-motor symptom in PD patients with prevalence rate reported to be as high as 90%¹³⁸.

Head trauma was first identified as a potential risk factor for PD by Martland in 1928 when repeated head injuries in boxers resulted in Parkinsonian symptoms along with cognitive decline, which he dubbed “punch drunk”¹³⁹. Head injury as a potential risk factor for idiopathic PD gained more attention in 1984 when Muhammad Ali was diagnosed with PD at the age of 42. Since Ali's diagnosis, there have been many epidemiological studies investigating the role of TBI history in PD predisposition and pathology. The results of these studies have been conflicting with roughly half reporting that a history of TBI increases the risk of PD^{140–149} while other studies report no such relationship^{150–162}. Of the studies reporting a significant relationship between TBI and PD, the odds ratio for risk of PD following head trauma ranged from 1.4–11.7¹⁶³.

One compelling study investigated the prevalence of PD among sets of twins. This is a strong way to control many of the extraneous variables contributing to the multifactorial etiology of PD like genetics, environmental exposures, etc. This study found a 3–4 fold increase in risk of PD if there was a history of TBI in one twin even when the average occurrence of TBI was 30 years prior to the onset PD¹⁴³. Interestingly, the researchers report a dose-response relationship as the risk for PD increased with multiple TBI¹⁴³. However, a recent review of 20+ epidemiological studies does little to support or refute this relationship between TBI history and PD¹⁶³.

Pathology

The main pathological finding of PD is the degeneration of dopaminergic neurons in the pars compacta of the substantia nigra, which leads to loss of dopamine in the striatum. Manifestation of clinical symptoms does not typically occur until roughly 80% of these dopaminergic neurons are depleted¹⁶³. Additionally, PD is characterized by mitochondrial dysfunction³⁵, oxidative stress³⁵, defective handling of proteins¹⁶⁴, inflammation¹⁶⁵, and presence of α -synuclein Lewy body pathology in the surviving dopaminergic neurons¹⁶⁶. α -Synuclein is a protein that has been described as one of the key neurodegenerative biomarkers in both familial and sporadic PD^{167,168}. Interestingly, the presence of Lewy body pathology and α -synuclein aggregation has been observed in the olfactory tracts prior to any other regions of the brain, which points to olfaction dysfunction as one of the first signs of PD¹⁶⁹. In addition to pathological changes observed in the cerebral cortex, immunohistochemistry studies have indicated increased α -synuclein in the cerebellum of PD patients, which contributes to the demyelination of neuronal tissue^{170,171}.

The pathophysiological changes associated with TBI are also well aligned with our current understanding of PD pathology. A common link between the two pathologies is the presence of α -synuclein. Recalling the previous discussion on the effects of DAIs, it is well established that the impaired axonal transport following microstructural white matter injuries leads to augmented accumulation of α -synuclein. As a universal component of Lewy body pathology, it is clearly implicated in the etiology of PD and TBIs have been found to increase and modify α -synuclein in both animals and humans^{40,41,172}. The gene coding for expression of α -synuclein, SCNA, has also been linked to PD and TBI. Specifically, the expansion of Rep1, a polymorphic mixed-dinucleotide repeat in the SCNA promoter region increases expression of this protein in both humans and animals, which consequently elevates risk of PD¹⁶⁷. One study investigating the effects of both SCNA and TBI history found that SCNA Long Rep1 carriers with a history of TBI were 6 times more likely to develop PD than non carriers of the at risk gene and no history of head trauma¹⁶⁷.

Neuroimaging

Conventional MRI studies using VBM to examine gray matter cerebral atrophy have been less conclusive for PD studies than the AD studies previously mentioned¹⁷³. The inconsistency of conventional MRI modalities may be derived from the motion artifacts and image ghosting caused by the motor impairments and tremor associated with PD. Several studies found no difference in whole brain volumetric measurements in PD patients when compared to age matched healthy controls^{174–176}. Two longitudinal studies, however, report an increased rate of annual brain volume loss and increased cerebral gray matter atrophy in PD patients^{177,178}. ROI studies examining the gray matter density and volume in specific regions of the brain have yielded more agreeable results. This ROI analysis indicates that PD patients experience significant atrophy in structures like the hippocampus, amygdala, orbitofrontal cortex, substantia nigra, primary olfactory cortex, and anterior cingulate^{179–184}. Increased global cerebral atrophy, similar to that observed in AD patients, is generally only observed in Parkinson's patients with dementia^{180–181}. Recalling the aforementioned VBM studies on TBI patients, it appears that one unifying regional finding between TBI and PD patients is significant hippocampal atrophy⁵⁸.

Researchers have also utilized diffusion tensor imaging to investigate the microstructural WM abnormalities contributing to PD. Due to the known degeneration occurring in the substantia nigra of PD patients, initial focus was placed on imaging this structure in the brain using DTI. A number of early studies found no WM differences between PD patients and healthy controls in the substantia nigra^{185–189}. More recent studies, however, have observed microstructural abnormalities in the substantia nigra indicated by reduced FA values and increased MD measures in PD patients^{190–196}. One team of researchers was able to successfully distinguish PD patients from age matched healthy controls using only DTI measures from the caudal portion of the substantia nigra¹⁹¹. DTI studies also highlight widespread WM abnormalities in PD patients in regions of the brain outside the substantia nigra. Researchers have found decreased FA values and increased MD values indicating microstructural damage in the CC, hippocampus, SLF, ILF, uncinate, cingulum, external capsule, corticospinal tract, regions of the frontal lobe, and bilaterally in the cerebellum^{193,197–199}. Additionally, DTI studies have revealed significant damage to the

olfactory tracts in PD patients, which elucidates olfaction dysfunction as a common symptom^{199–202}. Another interesting DTI finding in PD patients is damage to the orbitofrontal cortex²⁰¹. This is a commonly observed feature in depression patients²⁰³, so this finding may be responsible for the high rate of comorbid depression in the PD population¹³⁸.

When re-examining the DTI studies performed on TBI patients, there are several commonalities that crossover to the PD population. Most notably, researchers observed chronic global increases in MD values and decreases in FA values in TBI patients indicating widespread WM structural abnormalities similar to that of PD patients^{72,77}. Additionally, researchers have found microstructural damage specific to the same individual ROIs in both groups of patients. In harmony with PD findings, WM structural abnormalities in TBI patients are observed in the CC, hippocampus, SLF, ILF, uncinate fasciculus, and the corticospinal tract^{68,79,82,204–206}.

fcMRI studies are also being applied to PD patients in order to delineate the abnormalities of ICNs that are contributing to the progression of their disease. Re-examining the unique pathophysiology of PD, it is evident that examining this disease from a network perspective is essential to properly understand it²⁰⁷. Degeneration of dopaminergic cells in the midbrain leads to dopamine depletion throughout the striatum²⁰⁸. This creates a neurochemical imbalance that impairs neuronal processing in the basal ganglia and propagates through dense corticostriatal connections to alter activity in other brain regions^{209,210}. With this in mind, it is clear that impairments within the functional architecture of the brain are highly relevant to the pathology of PD and fcMRI studies can yield key insight on this matter. fcMRI studies investigating PD have tried to focus on mapping the functional architecture of corticostriatal connectivity since the pathology of PD is known to affect these structures. Multiple studies have reported disrupted functional connectivity within corticostriatal loops^{207,211–214}. Interestingly, two of these studies observed an anterior shift in functional connectivity resulting in increased connectivity between the anterior putamen and cortical regions^{207,212}. This is most likely a compensatory effect as the anterior putamen is known to be less affected by neurochemical alterations than the posterior putamen²⁰⁷. It could also be due the dopaminergic medication taken by PD patients since de novo patients displayed no increased FC in the anterior putamen²¹⁴. The effects of L-DOPA on the fcMRI results are still not entirely known, but multiple studies have reported that dopaminergic medication will at least partially restore the functional ICNs of PD patients^{215–218}. The increase in functional connectivity for patients receiving dopamine could also be a natural compensatory effect since patients receiving medications have generally had PD for significantly longer than de novo patients²¹⁴. Other fcMRI studies investigating ICNs of PD patients have reported increased functional connectivity in the cortical motor areas^{211,219}. One study reporting hyperconnectivity between the subthalamic nucleus and the motor cortex suggests that this abnormal coupling is responsible for PD rigor and tremor²¹⁹.

There are fewer fcMRI studies on TBI patients that have examined the corticostriatal ICNs with the same specificity as the PD studies above. However, there have been several interesting findings that may be related to the functional connectivity impairments reported in PD patients. One study investigating the sub-acute effects (mean time since injury: 60

days) reports significant functional connectivity impairments in the basal ganglia, motor network, sensorimotor cortex and the caudate¹⁰⁷. Another study reports reduced inter-hemispheric functional connectivity among motor regions in TBI patients²²⁰. Further investigation on the chronic and acute effects of TBI on the corticostriatal ICNs is necessary to delineate their influence on the development and progression of PD.

A significant portion of the PET research in the realm of PD is focused on using ¹⁸F-DOPA as a tracer to study dopaminergic metabolic activity rather than employing FDG to study CMRgl. These findings yield interesting results with the majority indicating decreased ¹⁸F-DOPA uptake in key nigrostriatal structures, primarily the posterior putamen²²¹. These are significant findings, but this review will primarily focus on FDG PET to investigate the effects of PD on CMRgl. The change in CMRgl resulting from PD is highly variable depending on the region of the brain²²¹. Significant increases in CMRgl are reported in bilateral lentiform nucleus, PCC, and parahippocampus²²², whereas significant reductions in CMRgl are observed in the temporal, parietal, frontal, occipital cortices and caudate of PD patients^{223,224}. Additionally, a longitudinal study examining PD patients at three time points spanning 4 years reports that disease progression is associated with increased CMRgl in the subthalamic nucleus, globus pallidus, dorsal pons, and primary cortex with declining CMRgl in the prefrontal and inferior parietal regions²²⁴.

As previously discussed, FDG PET studies investigating the effects of head trauma on CMRgl are highly variable depending on the time since injury. Future FDG PET studies on TBI patients are necessary to adequately compare these acute and chronic findings to those observed in PD patients.

Amyotrophic Lateral Sclerosis

Epidemiology

ALS is less prevalent than AD and PD with an incidence rate of roughly 5 per 100,000 people when considering the general population, but it is still regarded as the most common Motor Neuron Disease (MND)²²⁵. It is a disease that progresses much quicker than other neurodegenerative diseases with 50% of ALS patients dying within three years of onset¹⁴. It is characterized clinically by progressive weakness, atrophy and spasticity of muscle tissue. These clinical manifestations are caused by degeneration of upper and lower motor neurons in the cortex, brainstem and spinal cord²²⁶. The underlying pathological mechanisms of ALS are less understood, but it is suspected that some of the characteristics of ALS are comparable to those of other NDs¹⁹.

As with AD and PD, it is not confirmed, but it is hypothesized that history of head trauma may be the main environmental risk factor for developing ALS later in life. Identification of a significantly higher incidence rate of ALS in professional athletes in sports like American football and soccer have led researchers to believe head injuries are a risk factor for ALS^{20,227–229}. A study of retired NFL players found that neurodegenerative mortality for ALS was four times higher than that of the general population²⁰. Another study indicates that professional Italian soccer players are 6.5 times more likely to develop ALS with a dose-response relationship between length of career and likelihood of disease²²⁸. These

findings suggest that a history of TBI predisposes individuals to ALS, a notion that was first proposed back in 1911²³⁰. However, once again, the epidemiological studies yield conflicting results as several found a significant relationship between previous TBI history and ALS^{19,231,232} while several provide evidence to refute this claim^{233–235}.

Pathology

There are still many unknown features contributing to the pathogenesis and progression of familial (10%) and sporadic (90%) ALS. Structurally, the motor components targeted by neuropathology of ALS are the upper motor neurons of the corticospinal tract and the functionally linked lower motor neurons of the brainstem and anterior horns of the spinal cord²³⁶. One consistent finding regarding the molecular pathology of ALS that is now a hallmark for the disease is the deposition of ubiquitin positive proteins throughout the central nervous system (CNS)^{237,238}. In recent years, researchers have further specified this hallmark of ALS to be a specific subset of ubiquitinated pathology known as TAR DNA-binding Protein 43 (TDP-43)²²⁶. As such, ALS is now classified as a TDP-43 proteinopathy. Another common feature of ALS pathology is a significant increase in microglial activity through the CNS, indicating widespread neuroinflammatory disease progression^{35,133,134}. Post-mortem studies indicate that levels of microglial inflammatory activity correlate with the rate at which ALS progresses^{133,134}.

There are similar pathological findings between ALS and TBI patients as well. Notably, the characteristic protein contributing to the neuropathology of ALS, TDP-43, is reportedly also found in TBI patients. One post-mortem study examined the brains of 12 patients with CTE, a disease that develops as the result of extensive and repetitive head trauma. Of these 12 cases, 10 displayed abundant TDP-43 proteinopathy widespread throughout the CNS and motor neurons²³⁹. Additionally, the increased microglial inflammatory activity related to the progression of ALS is also observed in TBI patients¹²⁷. This neuroinflammatory response following head trauma is chronic and progressive for up to 18 years following the injury, which may lead to greater risk of developing ALS^{127,128}. This perpetual neuroinflammatory response, triggered by DAIs, is likely a key contributor to much of the cellular damage and pathology that has been previously discussed^{240,241}. After a prolonged inflammatory response, the microglia become over-activated and induce detrimental neurotoxic effects by releasing multiple cytotoxic substances and oxidative metabolites²⁴². Additionally, the release of these neurotoxic substances can influence the activation of astrocytes and, subsequently, produce glial scar formation. Though astrocytes can provide neurotrophic support and guidance for axonal growth following CNS injury, the prolonged astrogliosis stemming from hyperactive inflammatory responses may inhibit axonal regeneration and impede functional recovery²⁴². The perpetual nature of neuroinflammatory responses following TBI may contribute to a number of different biological processes that predispose individuals to a greater risk of neurodegenerative disease.

Neuroimaging

Several studies utilizing conventional MRI to obtain VBM measures for ALS patients yield comparable results to those observed in TBI, AD and PD populations with an overall trend of global brain atrophy^{243–245}. In recent years, many studies have turned to DTI to assess

the WM structural connectivity in the motor systems of ALS patients. The focal point of many of these studies has been the corticospinal tract, which can be visualized as the white matter “highway” connecting the upper and lower motor neurons²⁴⁶. Not surprisingly, these studies report significant WM impairments in the corticospinal tract of ALS patients^{247–251}. Further investigation into the motor connectome of ALS patients reveals widespread WM structural impairments in primary motor regions (precentral gyrus and paracentral lobule), supplementary motor areas (caudal middle frontal gyrus), parts of the basal ganglia, PCC, and the precuneus²⁴⁶. The corpus callosum is another region that is consistently shown to have microstructural impairments in ALS patients²⁵².

fcMRI studies also indicate impairments of the functional architecture in brains of ALS patients, that often correlate with the level of WM damage determined via DTI. Specifically, increased levels of functional connectivity, indicative of inefficient networks, is observed in sensorimotor, premotor, prefrontal and thalamic regions of ALS patients²³⁶. Another fcMRI study found decreased functional connectivity between the left and right primary motor cortices, indicating a functional disconnect between hemispheres in ALS patients²⁵³. fcMRI findings regarding the DMN in ALS patients indicate decreased activity in the DMN as is observed in other neurodegenerative diseases²⁵⁴.

PET is another modality that has been employed to study ALS patients. One study using PK PET to evaluate neuroinflammation reports that there is a significant increase in inflammation in the motor cortex, dorsolateral prefrontal cortex, and thalamus of ALS patients²⁵⁵. Similar findings were found as a chronic response to TBI, specifically an increase in inflammation of the thalamus, as indicated by greater uptake of PK, for up to 18 years following a single head injury¹²⁷. Additionally, the FDDNP PET scans that were designed to examine tau pathology in vivo displayed significant increases in tau in retired NFL players¹³⁵. Tau pathology is a contributor to the pathogenesis of ALS so the elevated levels of tau following repetitive head injuries may be predisposing these individuals to a higher risk of ALS. There is a strong link between ALS and TBI patients regarding the PET findings, but additional neuroimaging studies investigating the chronic effects of TBI are required to delineate the functional and structural changes that may contribute to the pathogenesis of ALS.

Chronic Traumatic Encephalopathy

Epidemiology

The incidence rate of CTE and the overall epidemiological statistics pertaining to the condition are still primitive. The clinical spectrum of disease that is now identified as CTE was first postulated as a disorder in 1928 by Harrison Martland who termed this disorder “punch drunk” since it was largely found in boxers following multiple hits to the head either in competition or training¹³⁹. This condition was further expounded and termed dementia pugilistica by Millspaugh in 1937 lending further medical validity to the disease²⁵⁶. Although it is neuropathologically similar to other NDs, dementia pugilistica was identified as a distinct neuropathological disorder in 1973 by Corsellis and it is now most commonly recognized as CTE²⁵⁷.

Not surprisingly, much of the work today surrounding CTE and its incidence rate still revolves around athletes and other populations with frequent exposure to head injuries. Omalu and colleagues made significant contributions to the field by expanding the scope of CTE from focusing solely on boxers to athletes in a number of other contact sports (i.e., American football, hockey, wrestling, etc.) as well as military veterans^{258–260}. An older study that is still frequently cited indicates that among ex-professional boxers the incidence rate of CTE is 17%²⁶¹. In a more current and comprehensive review, McKee and colleagues indicate that the incidence of CTE in populations with frequent exposure to head injuries is at least 17%, but they speculate that the incidence rate is actually much higher¹³⁶. After post-mortemly analyzing the brains of 85 individuals (all of which were either contact sport athletes or military veterans) with a history of repetitive mTBI and subconcussive head trauma, evidence of CTE was observed in 80% of the brains²⁶². However, it is worth noting that this is a biased sample that over represents the actual incidence of CTE because families are far more likely to consider neuropathologic examination if they noticed symptoms representative of ND in their loved ones before their passing. It is also important to note when examining the epidemiology of CTE that the sample size is extremely small due to relatively the rare opportunity for post-mortem examination required to make definitive diagnoses.

Another key limitation in obtaining valid epidemiological statistics for CTE is the unreliable nature of the differential diagnosis for CTE versus other NDs. Individuals with CTE may present with symptoms that mimic those of AD, PD, or ALS and are subsequently misdiagnosed with one of these more well known conditions. This is why most individuals with CTE do not receive a proper diagnosis until post-mortem examination of their brains. In fact, one large review observed that when examining 68 post-mortemly confirmed cases of CTE, 37% had co-morbid neurodegenerative disease, the most common being a motor neuron disease like ALS²⁶². These limitations are further amplified by the work of Hazrati and colleagues after examining the brains of 6 individuals with repetitive exposure to head trauma. They report that all six cases had evidence of ND, but not a single case was purely CTE and the three individuals with CTE pathology also had concomitant pathology of other NDs²⁶³. Additional research is required to create improved diagnostic criteria, discover objective biomarkers, and enhance our understanding of the progressive neuropathology of CTE in order to properly diagnose this disease in vivo.

CTE is also uniquely difficult to study because all clinical examinations must be done retrospectively through interviews conducted with family members of the deceased. This adds a challenging element when attempting to delineate the clinical progression of CTE. However, it is generally understood that the neuropathology of this condition leads to emotional, cognitive, and motor control impairments. Corsellis proposed three clinical stages of CTE in 1973 that are still supported today. The first stage typically features affective disturbances and psychotic symptoms relating to irritability, aggression and depression. As the disease progresses, individuals with CTE are affected by social instability, erratic behavior, memory loss and early signs of Parkinsonism during the second stage. The third stage is characterized by worsening dementia and severely impaired motor control either in the form of Parkinsonism or motor neuron disease^{257,136,264,265}. Additionally, clinical presentation generally occurs at a younger age than other NDs with a

recent review indicating that the average age of onset for CTE is 42¹³⁶. However, it can present much earlier in life and the earliest known case of CTE was found in a 21 year old athlete following an abrupt suicide.

CTE is an apt representation of the insidious nature of head injuries as the neurological damage slowly accumulates and continues to progress many years after the exposure(s) to head trauma. It is distinct from the acute sequelae of a single concussive event and it is evident that this condition is not merely a severe case of prolonged concussive syndrome²⁶⁶. In fact, several of the post-mortem confirmed cases of CTE had no medical history of any TBI, including mild concussions^{136,266,267}. As such, many researchers are currently investigating the aggregate effects of repetitive subconcussive hits to the head that may exist without any medical record. This is a cause for concern considering that high school and collegiate athletes playing contact sports like football can be exposed to well over one thousand subconcussive hits to the head in a single season^{268,269}.

Pathology

Though CTE is still a nascent field of research compared to the aforementioned NDs, there are many recognizable gross neuropathological features. CTE is characterized by extensive atrophy in both cerebral hemispheres (particularly in the frontal, temporal and parietal lobes) as well as subcortical structures including the olfactory bulbs, thalamus, mammillary bodies, brainstem, and cerebellum^{136,257,267}. This atrophy results in a significant reduction in brain mass¹³⁶. Additional gross features indicative of CTE are cavum septum pellucidum, septal fenestrations, pallor of the locus coeruleus & substantia nigra, enlargement of the third & lateral ventricles, and thinning of the corpus callosum^{136,257,267}.

Additionally, there are extensive findings elucidating the microscopic alterations that contribute to the pathology of CTE. Like other NDs, abnormalities in protein deposition is a hallmark of CTE. The primary protein of interest is Tau, which is present in the form of NFTs, neuropil threads and glial tangles. Tau is also a feature of AD, but there are distinct differences in the presentation of Tau in CTE. Unlike AD, NFT clusters are generally denser in CTE and they form at the depths of the sulci, around small blood vessels and are preferentially distributed to superficial cortical layers^{136,267}. This tau pathology is randomly distributed in the brains of CTE individuals while it has been observed to be more uniformly distributed in cases of AD. In CTE, NFTs are most commonly observed in the dorsolateral, subcallosal, insular, temporal, dorsolateral parietal, and inferior occipital cortices as well as the olfactory bulbs, hippocampus, amygdala and subcortical white matter including the external capsule, anterior & posterior commissures, thalamic fasciculus and fornix¹³⁶.

Increased A β deposition is less common in individuals with CTE compared to what has been reported in AD patients. Abnormal A β deposits are found in 40–45% of individuals in CTE compared to nearly all cases of AD²⁶⁶, and some studies show no presence of A β in their cases of CTE²⁶⁰. The role of Lewy body pathology, specifically α -Synuclein, in the development of CTE has also been investigated. In McKee's most recent review, 22% of the 85 confirmed cases of CTE also possessed abnormal levels of α -Synuclein. However, these individuals with Lewy bodies were significantly older than the CTE cases without Lewy body pathology²⁶². Another feature of CTE is the presence of TDP-43, which is a protein

that was previously discussed for its role in ALS pathology. McKee et al observed widespread TDP-43 in 80% of their 12 CTE cases, many of which were experiencing symptoms indicative of motor neuron disease²³⁹. A larger review indicates that of the 71 individuals with repetitive head injuries examined for TDP-43, 61 of them had TDP-43 proteinopathy in multiple brain regions²⁷⁰.

Neuroimaging

Considering a conclusive diagnosis CTE can not be made until post-mortem examination of the brain, there is very little research available that utilizes neuroimaging modalities to study the brains of living individuals who are afflicted with this progressive disease. From the current understanding of the neuropathology associated with CTE, there are several neuroimaging techniques that may be able useful in the diagnosis of CTE.

Structural MRI may be used to identify cerebral atrophy in vivo, which is a hallmark of CTE currently measured by weighing the brain during post-mortem examination. A recent review examined the structural MRI results of 100 “unarmed combatants” with extensive exposure to head trauma. There were several findings within this population of 100 individuals that are suggestive of CTE including 59% hippocampal atrophy, 43% cavum septum pellucidum, 24% cerebral atrophy, and 19% with enlarged lateral ventricles²⁷¹.

DTI is another neuroimaging modality that will be essential as researchers attempt to delineate the etiology of CTE. As the aforementioned articles clearly indicate, TBIs lead to microstructural damage in the WM of the brain that can be examined through DTI. A recent review indicates that these studies consistently report microstructural abnormalities following head trauma, but the exact nature of these abnormalities varies due to the heterogeneity of brain injuries⁵⁴. These varying results are also attributable to the cross-sectional design of the studies performed. Brain damage following single or multiple head injuries has been shown to be progressive, so it is reasonable to expect that these neuroimaging findings will vary depending on the time elapsed since the injury. Longitudinal studies are required to understand the dynamic nature of TBIs and to delineate these alterations to the brains microstructural integrity during recovery. There are several DTI studies examining the chronic effects of not only TBIs, but also repetitive subconcussive events that may provide further insight to the progression of CTE. One such study utilizing DTI to compare the brains of veterans with blast exposure to those without blast exposure found global patterns of reduced FA in the WM of the blast exposure group²⁷². Another study investigating the effects of multiple subconcussive hits to the head in HS athletes reports abnormal MD and FA values even in athletes with no previously diagnosed TBI²⁷³.

fMRI and PET studies examining the functional and neuroenergetic abnormalities in individuals with repetitive exposure to head trauma are also essential to better understand CTE. A FDG-PET study of boxers found hypometabolism in PCC, parieto-occipito frontal lobes, and the cerebellum following chronic exposure to subconcussive events²⁷⁴. Another study revealed that soldiers with multiple blast exposures (mean of 12) revealed decreased metabolism in cerebellum, vermis, pons, and medial temporal lobe²⁷⁵. A comparable study using resting state fMRI reports that retired NFL players exhibit decreased functional

connectivity within the dorsal fronto-parietal network²⁷⁶. Additionally, they exhibited hyperfrontality and required increased activation in the frontal lobe during tasks of executive function²⁷⁶. Another study employing fMRI to examine the functional activity of HS athletes who were equipped with accelerometers in their helmets to track head impacts over the course of the season indicates that the effects of these repetitive head injuries can materialize quickly. The athletes were tested both before and after the season and the fMRI results indicate that even players without diagnosed concussions experienced neurophysiological impairments with significant alterations to the dorsolateral prefrontal cortex (DLPFC), the superior frontal gyri, and left middle frontal gyri²⁷⁷. It is worth noting that these neurophysiological abnormalities exhibited in the fMRI are strongly correlated with neurocognitive deficits and impaired verbal memory. Additionally, a correlation was observed between impaired fMRI activity and the number of subconcussive hits to the head tracked by the accelerometer over the course of the season²⁷⁷.

These studies highlight the need for improved surveillance of head injuries since many of these results occur in the absence of a diagnosed TBI, especially in individuals with frequent exposure to subconcussive events. Properly identifying these at risk populations is essential to delineate the link between head injuries and all forms neurodegenerative disease. Additionally, these findings point to the marked absence of longitudinal data. Though these neuroimaging findings are compelling, they are inherently ambiguous in nature given the fact that CTE can not be diagnosed until after the individual is deceased. Prospective MRI studies examining at risk populations, both before and after signs of ND, are required to fill this knowledge gap. Though it is a fairly morbid proposition, it would be beneficial to perform a study tracking these cases longitudinally for an eventual post-mortem assessment of CTE, which can then be compared against previously acquired in vivo neuroimaging data. To account for the vast heterogeneity and the multifaceted nature of the progressive effects of head injuries, future studies should employ multimodal neuroimaging techniques in order to comprehensively scan the brain for subtle abnormalities.

Discussion and Future Directions

In order to more effectively develop therapeutic targets to treat, and perhaps prevent the development of neurodegenerative disease, it is essential to identify the key steps responsible for the pathological cascade progressing from TBI to neurodegenerative disease. Between the initial brain reserve hypothesis, the metabolism hypothesis, and the overall intertwined natures of their pathologies, it is evident that TBI and neurodegenerative disease are not mutually exclusive. So why have the results of these large epidemiological studies been so conflicting? It is possible that the relationship simply does not exist or it is not strong enough as indicated by previous epidemiological studies. However, an overwhelming trend in the neuroimaging and pathological findings suggests otherwise.

Upon examining the existing epidemiological case studies, it is apparent that there is a fundamental problem in the way this topic is being investigated. There is no consistent definition of TBI used across these studies, and therefore, each epidemiological study classifies participants with history of TBI under a different set of criteria (Table 2). It is unreasonable to expect the findings to be consistent and valid across multiple studies while

using different criteria to identify one of the two variables that are being compared. It is imperative to work towards a more uniform approach to investigate this relationship by introducing an improved retrospective head trauma screening tool based off current CDC guidelines for TBI. Settling on a gold standard that can be used to effectively identify TBI history in a retrospective fashion will improve the homogeneity of findings in future studies.

In addition to their inconsistencies, many of the existing epidemiological studies use dated definitions and guidelines for retrospectively identifying head trauma. This, of course, is understandable considering the pace at which our understanding of head injuries is growing. In the last 11 years alone, the operational definition of concussions has been altered each of the four times a consensus statement has been released by a team of experts meeting at the International Conference for Concussion in Sport^{282–285}. The most current definition released by this panel reads: “Concussion is a brain injury and is defined as a complex pathophysiological process affecting the brain, induced by biomechanical forces. Several common features that incorporate clinical, pathologic and biomechanical injury constructs that may be utilized in defining the nature of a concussive head injury include:

1. Concussion may be caused either by a direct blow to the head, face, neck or elsewhere on the body with an ‘impulsive’ force transmitted to the head.
2. Concussion typically results in the rapid onset of short-lived impairment of neurological function that resolves spontaneously. However, in some cases, symptoms and signs may evolve over a number of minutes to hours.
3. Concussion may result in neuropathological changes, but the acute clinical symptoms largely reflect a functional disturbance rather than a structural injury and, as such, no abnormality is seen on standard structural neuroimaging studies.
4. Concussion results in a graded set of clinical symptoms that may or may not involve loss of consciousness. Resolution of the clinical and cognitive symptoms typically follows a sequential course. However, it is important to note that in some cases symptoms may be prolonged.”²⁸²

In essence, the sensitivity in nearly all of these previous epidemiological studies is too low to adequately assess TBI history in a retrospective fashion. The vast majority of these studies classify subjects as having a history of TBI only when they report a blow to the head resulting in loss of consciousness (LOC) or requiring medical attention. Both of these approaches are fundamentally flawed when considering current CDC guidelines for head trauma. It is now well established that TBIs can occur in the absence of LOC and, in fact, the majority of TBIs occur without LOC^{286,287}. Furthermore, many people are unaware of their sustained injuries, which leads to a substantial portion of TBIs going unreported⁷.

In addition to the distinct lack of a common definition for what constitutes a TBI, many studies use dissimilar and vague approaches to acquire this key piece of medical history (Table 2). Some large epidemiological studies use medical databases and rely on medical records to link TBI history with neurodegenerative diseases. Recalling the aforementioned findings in the CDC’s 2003 Report to Congress, it is clear that this is not sufficient since this method may only account for the 12% of mTBI patients that are hospitalized³. Some studies

rely on phone interviews, others employ “standardized” interviews with trained clinicians, and a large number of them utilize “standardized” medical history questionnaires. A key flaw, however, is that these questionnaires and interview methods are only standardized within that individual study’s patient population. There is no transcript of the interview format or name of the questionnaire provided, which leads to these studies using dissimilar and undisclosed methodologies resulting in a lack of standardization across the field. Additionally, many times these standardized questionnaires and interviews only offer a quick “Yes/No” question to head trauma that is buried in a long list of other previous ailments.

In their 2003 Report to Congress, the CDC tangentially addressed this issue by pointing out the inadequacies of current head trauma screening tools and calling for improved methods to obtain more accurate TBI surveillance data⁷. Ten years later, the Institute of Medicine still felt the need to echo this sentiment by listing improved concussion surveillance as one of their top priorities in their 2013 report²⁸⁸. Robust head trauma surveillance tools have been developed for specific populations like military personnel (Brief Traumatic Brain Injury Screen, BTBIS)²⁸⁹ and athletes (Sports Concussion Assessment Tool 3, SCAT-3)²⁸², but these are often incompatible with the general population. Furthermore, many of these TBI screening tools focus on events occurring in the more immediate past rather than focusing retrospectively on events spanning one’s lifetime.

In addition to creating a retrospective TBI screening tool that is all-encompassing, it also needs to be composed with special consideration pertaining to its language and terminology. An important study investigating the incidence of TBI in university athletes highlights the immense variability that is derived from the language used in head trauma questionnaires²⁹⁰. Immediately following the season, football and soccer players were asked whether or not they experienced a blow to the head resulting in a concussion with 16.5% and 12.4% of players, respectively, reporting a concussion. This same group was then given a questionnaire with altered language that focused on whether they experienced the common symptoms of concussions following a hit to the head. Suddenly, the self-reported rate of players experiencing concussion symptoms following a blow to the head jumped to 70.4% and 62.7% of all football and soccer players²⁹⁰. Of the 70.4% of football players experiencing symptoms of a concussion, only 23% of them realized they had suffered a concussion compared with only 19% of soccer players recognizing their symptoms as a concussion²⁹⁰. This study perfectly illustrates the significant limitation of underreported TBIs even as our awareness of head injuries has grown. Essentially, 80% of these athletes never even knew they suffered a concussion so they would not have sought medical attention for their head injuries and would have falsely responded “no” when asked if they had a history of head trauma, which highlights the problem with current methodologies employed by large epidemiological studies.

Even with the heightened TBI awareness in recent years, athletes still frequently omit reporting head injuries for a myriad of reasons. One study used a detailed questionnaire immediately following the season asking high school football players (n=1532) if they had suffered a concussion during that previous season²⁹¹. Of the 15% who responded yes, indicating they knowingly suffered a concussion, 53% of them indicated that they never

reported the injury with the top two reasons being they “did not think it was serious enough” or they did not want to leave the game²⁹¹. This is dangerous on many levels. Not only are these athletes at risk of second impact syndrome and further damage if they continue playing²⁹², but these injuries are likely to perpetually go unaccounted for. In addition to there being no medical record of these injuries, many of these athletes will write-off these childhood incidents as noninjurious events after living asymptotically for a number of years and fail to retrospectively report them if presented with a simple “yes/no” questionnaire later in life. This is likely contributing to the overwhelming variability and inadequacy in responses to current questionnaires used to assess TBI history.

Additionally, it is reasonable to expect that the number of unreported mTBIs is even higher when examining the target populations of epidemiological studies investigating neurodegenerative diseases. Naturally, it will be more difficult to recall individual events that may have occurred decades earlier. Furthermore, others must take into account how incredibly low our awareness of head traumas was several decades ago. An accurate answer cannot be expected from a ~60 year old participant if they are simply asked if they have ever suffered a concussion or rely on medical data for head traumas. It is highly likely that they might have suffered a concussion forty years earlier either as an athlete or in an accident, but they were never properly aware of it. A review of NCAA data for 15 sports showed that the overall reported concussion rate doubled from 1.7 to 3.4 concussions per 1,000 athletic exposures from 1988 to 2003²⁹³. Helmet technology has unquestionably improved during this same time span, which suggests that in recent years concussion rates have increased as a result of our increased awareness of head injuries. A new and improved retrospective screening tool is required to make advancements in addressing this knowledge gap from previous decades.

With this information, it is evident that there are three essential components to an effective TBI screening tool for this population: 1) terminology focusing on the symptoms of head injuries rather than simply the incidence, 2) questions geared towards potential exposures for the general population as opposed to focusing on specific factions (i.e., sports), and 3) questions that are all-encompassing in nature rather than focusing on shorter time frames. After an extensive literature review, there is no evidence of a questionnaire that accounts for all three of these components. Existing epidemiological studies that attempt to retrospectively assess TBI history do so ambiguously and inconsistently across studies (Table 2). Some rely on medical histories, which can miss up to 88% of TBIs if they only account for hospitalizations^{3,8}. Other epidemiological studies only include head injuries that resulted in LOC, which does not account for up to 90% of mTBIs⁷. Another common approach to assess TBI history in these studies is through an interview with a trained clinician, but these interviews vary for each study and add an additional heterogeneous element to what is already an ambiguous task.

In an attempt to fill this void, the authors developed the Retrospective Screening of Traumatic Brain Injury (RESTBI) Questionnaire (see sites.duke.edu/restbi). This retrospective surveillance tool was designed with the goal of increasing the sensitivity to head injuries in order to recognize and identify the many TBIs that are currently unaccounted for. Additionally, the intent was to make a head trauma screening tool that can

be used across various populations in order to increase consistency between different studies. With that in mind, the RESTBI was created so it could be handed out to collegiate athletes with the same effectiveness and accuracy that would be achieved if it was given to their grandparents. In order to do so, the RESTBI uses a framework for each question that will help elderly populations recall specific incidences where they may have been exposed to a potential head injury decades earlier that they are otherwise likely to forget. Additionally, the language and terminology found in the RESTBI focuses on the symptoms following TBIs due to the findings from Delaney and colleagues²⁹⁰. This should work towards addressing the knowledge gap from older populations who are less aware of what constitutes a head injury and may be unaware of previous injuries sustained. Finally, the fact that this is a questionnaire, rather than an interview form, will help yield increased reproducibility from different groups of researchers. It is important to note that, at this time, the authors are in process of validating the RESTBI. However, for the reasons listed above, the RESTBI has strong potential to increase the sensitivity for the retrospective surveillance of TBIs.

In addition to its function in epidemiological studies, the RESTBI could serve a vital role for nearly every neuroimaging study. It is indicated by the studies investigating TBI populations listed above that head traumas significantly alter the brain's anatomy, metabolism, and connectivity, both functionally and structurally. This is significant in terms of investigating the effects of TBI on the aging brain, but the scope of this problem may be much larger. How many neuroimaging studies might have inaccurate findings because they did not properly account for history of head trauma? This is a significant variable that is currently being inadequately assessed. All studies should consider utilizing a comprehensive and retrospective screening tool like the RESTBI to provide an extra data point to reference throughout the study. It may be the key piece in understanding the results for a study investigating ICNs (or some other topic where TBIs are not the focal point of the study) and it could potentially explain anomalies found in the data set.

This review also highlights the necessity for additional longitudinal neuroimaging studies that focus on the brain at different time points following head trauma. There are many significant findings for the brains acute and sub-acute responses to head injury, but the current neuroimaging data available fails to investigate the chronic effects of remote TBI (~10 years post injury). Previous neuroimaging studies are all either focused on the immediate days and months following a head injury or the disease state that is occurring sometimes decades later. There is a massive and literal gap in the data. There are no studies providing data from asymptomatic, and otherwise healthy, adults that investigate the chronic and progressive effects of TBI history. Studying this population may provide vital information regarding pathogenic cascade following TBI. There needs to be a paradigm shift from the traditional view that TBIs are an acute, static injury towards treating them as complex events with progressive damage to the brain. Studies have shown perpetual damage in TBI patients progressing up to 18 years following TBI^{127,128}, so it is imperative to track these ongoing impairments longitudinally through multimodal neuroimaging studies in order properly treat and prevent further damage.

There are likely tens of millions of people who are living with a previously sustained head injury, many of which are undiagnosed. Since TBI awareness has only grown in recent years, many of these individuals who may have hit their head decades ago are likely to have shrugged off a brief state of altered consciousness and disregard these instances as noninjurious events after years of living symptom free. However, as a result of these undiagnosed head injuries, it is reasonable to hypothesize that these individuals may be experiencing a number of progressive structural and functional abnormalities within their brain that are currently unnoticed. In addition to the perpetual neuroinflammatory response that is potentially still ongoing from the initial injury, they could have progressively increasing CMRgl levels and hyperactivity in the DMN to compensate for the worsening FA and MD in the axons that structurally connect their brain, all of which may contribute to abnormal protein deposition and predispose them to neurodegenerative disease. There is an overwhelming number people who fit this description; these adults are otherwise healthy until it is too late and they reach a point where their brain's compensatory mechanisms eventually fail leading to neurodegenerative disease. In the CDC's most recent report, TBI is referred to as the "silent epidemic" because many of the lasting complications from head injuries may not be readily apparent as is the case in many of these purportedly asymptomatic adults⁶. The neuroimaging technology is rapidly evolving to properly examine these mechanisms so the next step is achieving improved methods to properly identify otherwise healthy adults with a history of TBI, even mTBIs that may have been previously undiagnosed. The RESTBI offers a potential solution and avenue to adequately address this growing "silent epidemic". It is evident that these neurodegenerative diseases are pathologically complex with multifaceted etiologies, but there is strong evidence suggesting TBIs may play prominent role. As more of these studies are completed and the mechanisms connecting TBI with neurodegenerative disease are identified, it will open the door for improved therapeutics that may have the potential to stop the pathogenic cascade and limit the prevalence of these devastating diseases.

Conclusion

Traumatic Brain Injuries are a growing epidemic affecting all demographics of our population on a global scale. As our understanding of these head injuries increases, we are made increasingly aware of their calamitous consequences that may lead to lifelong disability and disease. Pathological and neuroimaging studies have presented a framework that displays the extensive overlap between TBIs and neurodegenerative disease. In order to adequately assess the relationship between head injuries and the predisposition of these neurodegenerative diseases, we must improve our ability to retrospectively assess past exposure to TBIs. The RESTBI is a potential solution to this problem that will hopefully be adapted by future studies in order to increase the validity and reliability of future epidemiological findings.

Acknowledgments

This research was partially supported by NIH R01 NS074045 (MHS and NC).

Abbreviations used

TBI	Traumatic Brain Injury
ROI	Region of interest
DAI	Diffuse Axonal Injury
DTI	Diffusion Tensor Imaging
WM	White Matter
FA	Fractional Anisotropy
MR	Magnetic Resonance
MD	Mean Diffusivity
CT	Computed Tomography
SLF	Superior longitudinal fasciculus
mTBI	Mild TBI
ILF	Inferior longitudinal fasciculus
ND	Neurodegenerative disease
CC	Corpus Collosum
AD	Alzheimer's disease
fMRI	Function magnetic resonance imaging
PD	Parkinson's disease
ICN	Intrinsic connectivity network
ALS	Amyotrophic Lateral Sclerosis
RSN	Resting state network
CTE	Chronic Traumatic Encephalopathy
fcMRI	Resting state function connectivity fMRI
APOE	Apolipoprotein E
DMN	Default Mode Network
Aβ	Amyloid-beta
PCC	Posterior cingulate cortex
NFL	Neurofibrillary tangles
PET	Positron emission tomography
NFL	National Football League
SPECT	Single photon emission computed tomography
VBM	Voxel-based morphometry

FDG	¹⁸ F-2-fluro-2-deoxyglucose
VBR	Ventricle to brain ratio
CMRgl	Cerebral metabolic rate for glucose
TBV	Total brain volume
PiB	Pittsburgh Compound-B
LOC	Loss of consciousness
PK	[11C](R)PK11195

References

1. Ruff RM, Iverson GL, Barth JT, Bush SS, Broshek DK, et al. Recommendations for diagnosing a mild traumatic brain injury: a National Academy of Neuropsychology education paper. *Arch Clin Neuropsychol*. 2009; 24:3–10. [PubMed: 19395352]
2. Faul, M.; Xu, L.; Wald, MM.; Coronado, VG. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002–2006. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.
3. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. *Br J Anaesth*. 2007; 99:4–9. [PubMed: 17573392]
4. World Health Organization. Geneva, Switzerland: 2006. Traumatic Brain Injury: Neurological Disorders: Public Health Challenges.
5. Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. *J Head Trauma Rehabil*. 2006; 21:375–378. [PubMed: 16983222]
6. Thurman DJ, Branche CM, Sniezek JE. The epidemiology of sports-related traumatic brain injuries in the United States: recent developments. *J Head Trauma Rehabil*. 1998; 13(2):1–8. [PubMed: 9575252]
7. Centers for Disease Control and Prevention. Atlanta, GA: 2003. National Center for Injury Prevention and Control. Report to Congress on mild traumatic brain injury in the United States: steps to prevent a serious public health problem.
8. Sosin DM, Sniezek JE, Thurman DJ. Incidence of mild and moderate brain injury in the United States, 1991. *Brain Inj*. 1991; 10:47–54. [PubMed: 8680392]
9. Sayed TE, Mota A, Fraternali F, Ortiz M. Biomechanics of traumatic brain injury. *Comp Methods Applied Mech and Engineering*. 2008; 197:4692–4701.
10. Broglio SP, Surma T, Ashton-Miller JA. High school and collegiate football athlete concussions: a biomechanical review. *Ann Biomed Eng*. 2012; 40:37–46. [PubMed: 21994058]
11. Broglio SP, Schnebel B, Sosnoff JJ, Shin S, Fend X, et al. Biomechanical properties of concussions in high school football. *Med Sci Sports Exerc*. 2010; 42:2064–2071. [PubMed: 20351593]
12. Guskiewicz KM, Mihalik JP, Shankar V, Marshall SW, Crowell DH, et al. Measurement of head impacts in collegiate football players: relationship between head impact biomechanics and acute clinical outcome after concussion. *Neurosurgery*. 2007; 61:1244–1252. [PubMed: 18162904]
13. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. *Dialogues Clin Neurosci*. 2009; 11:111–128. [PubMed: 19585947]
14. Migliore L, Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. *Mutat Res*. 2009; 667:82–97. [PubMed: 19026668]
15. Kalache A, Gatti A. Active ageing: a policy framework. *Adv Gerontol*. 2003; 11:7–18. [PubMed: 12820516]

16. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. *Nat Med.* 2004; 10:1055–1063. [PubMed: 15459709]
17. Shively S, Scher AI, Perl DP, Diaz-Arrastia R. Dementia resulting from traumatic brain injury: what is the pathology? *Arch Neurol.* 2012; 69:1245–1251. [PubMed: 22776913]
18. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. *Mov Disord.* 2013; 28:1222–1229. [PubMed: 23609436]
19. Chen H, Richard M, Sandler DP, Umbach DM, Kamel F. Head injury and amyotrophic lateral sclerosis. *Am J Epidemiol.* 2007; 166:810–816. [PubMed: 17641152]
20. Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. *Neurology.* 2012; 79:1970–1974. [PubMed: 22955124]
21. Finder VH. Alzheimer's disease: a general introduction and pathomechanism. *J Alzheimers Dis.* 2010; 22(Suppl 3):5–19. [PubMed: 20858960]
22. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, et al. Current concepts in mild cognitive impairment. *Arch Neurol.* 2001; 58:1985–1992. [PubMed: 11735772]
23. Guskiewicz KM, Marshall SW, Bailes J, McCrea M, Cantu RC, et al. Association between recurrent concussion and late-life cognitive impairment in retired professional football players. *Neurosurgery.* 2005; 57:719–726. [PubMed: 16239884]
24. Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on: a partial replication. *J Neurol Neurosurg Psychiatry.* 2003; 74:857–862. [PubMed: 12810767]
25. Schofield PW, Tang M, Marder K, Bell K, Dooneief G, et al. Alzheimer's disease after remote head injury: an incidence study. *J Neurol Neurosurg Psychiatry.* 1997; 62:119–124. [PubMed: 9048710]
26. Sullivan P, Petitti D, Barbaccia J. Head trauma and age of onset of dementia of the Alzheimer type. *JAMA.* 1987; 257:2289–2290. [PubMed: 3573227]
27. Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. *Ann Neurol.* 1993; 33:258–266. [PubMed: 8498809]
28. Mehta KM, Ott A, Kalmijn S, Slooter AJ, van Duijn CM, et al. Head trauma and risk of dementia and Alzheimer's disease: The Rotterdam Study. *Neurology.* 1999; 53:1959–1962. [PubMed: 10599765]
29. Koponen S, Taiminen T, Kairisto V, Portin R, Isoniemi H, et al. APOE- ϵ 4 predicts dementia but not other psychiatric disorders after traumatic brain injury. *Neurology.* 2004; 63:749–750. [PubMed: 15326261]
30. Mayeux R, Ottman R, Maestre G, Ngai C, Tang M. Synergistic effects of traumatic head injury and Apolipoprotein-epsilon4 in patients with Alzheimer's disease. *Neurology.* 1995; 45:555–557.
31. Dardiotis E, Fountas KN, Dardioti M, Xiromerisiou G, Kapsalaki E, et al. Genetic association studies in patients with traumatic brain injury. *Neurosurg Focus.* 2010; 28:E9. [PubMed: 20043724]
32. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. *Neurology.* 2000; 55:1158–1166. [PubMed: 11071494]
33. Jiang X, Jia LW, Li XH, Cheng XS, Xie JZ, et al. Capsaicin ameliorates stress-induced Alzheimer's disease-like pathological and cognitive impairments in rats. *J Alzheimers Dis.* 2013; 35:91–105. [PubMed: 23340038]
34. Finder VH, Glockshuber R. Amyloid-beta aggregation. *Neurodegener Dis.* 2007; 4:13–27. [PubMed: 17429215]
35. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature.* 2006; 443:787–795. [PubMed: 17051205]
36. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, et al. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. *J Neurol Neurosurg Psychiatry.* 1994; 57:419–425. [PubMed: 8163989]
37. Johnson. 2011

38. Hoshino S, Tamaoka A, Takahashi M, Kobayashi S, Furukawa T, et al. Emergence of immunoreactivities for phosphorylated tau and amyloid-beta protein in chronic stage of fluid percussion injury in rat brain. *Neuroreport*. 1998; 9:1879–1883. [PubMed: 9665619]
39. Smith C, Graham DI, Murray LS, Nicoll JA. Tau immunohistochemistry in acute brain injury. *Neuropathol Appl Neurobiol*. 2003; 29:496–502. [PubMed: 14507341]
40. Smith DH, Uryu K, Saatman KE, Trojanowski JQ, McIntosh TK. Protein accumulation in traumatic brain injury. *Neuromolecular Med*. 2003; 4:59–72. [PubMed: 14528053]
41. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. *Exp Neurol*. 2007; 208:185–192. [PubMed: 17826768]
42. Gentleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW. Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. *Neurosci. Lett*. 1993; 160:139–144. [PubMed: 8247344]
43. Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smith DH. A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. *Brain Pathol*. 2009; 19:214–223. [PubMed: 18492093]
44. Grady MS, McLaughlin MR, Christman CW, Valadka AB, Fligner CL, et al. The use of antibodies targeted against the neurofilament subunits for the detection of diffuse axonal injury in humans. *J Neuropathol Exp Neurol*. 1993; 52:143–152. [PubMed: 8440996]
45. Uryu K, Giasson BI, Longhi L, Martinez D, Murray I, et al. Age-dependent synuclein pathology following traumatic brain injury in mice. *Exp Neurol*. 2003; 184:214–224. [PubMed: 14637093]
46. Ashburner J, Friston K. Voxel-based morphometry: The methods. *NeuroImage*. 2000; 11:805–821. [PubMed: 10860804]
47. Frisoni GB, Geroldi C, Beltramello A, Bianchetti A, Binetti G, et al. Radial width of the temporal horn: a sensitive measure in Alzheimer disease. *AJNR Am J Neuroradiol*. 2002; 23:35–47. [PubMed: 11827874]
48. Baron JC, Chetelat G, Desgranges B, Percey G, Landeau B, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. *Neuroimage*. 2001; 14:298–309. [PubMed: 11467904]
49. Bigler ED, Tate DF. Brain volume, intracranial volume, and dementia. *Invest. Radiol*. 2001; 36:539–546. [PubMed: 11547042]
50. Bigler ED. Traumatic brain injury, neuroimaging, and neurodegeneration. *Front Hum Neurosci*. 2013; 7:395. [PubMed: 23964217]
51. Johannessen DJ, Mohs CM, Lawlor BA, Altstiel LD. Early Markers of Disease Expression in Alzheimer's. *Chronic Diseases: Perspectives in Behavioral Medicine*. 2013:21–31.
52. Fratiglioni L, Wang HX. Brain reserve hypothesis in dementia. *J. Alzheimers Dis*. 2007; 12:11–22. [PubMed: 17851191]
53. Skoog I, Olesen PJ, Blennow K, Palmertz B, Johnson SC, et al. Head size may modify the impact of white matter lesions on dementia. *Neurobiol Aging*. 2012; 33:1186–1193. [PubMed: 21420196]
54. Shenton ME, Hamoda HM, Schneiderman JS, Bouix S, Pasternak O, et al. A review of magnetic resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury. *Brain Imaging Behav*. 2012; 6:137–192. [PubMed: 22438191]
55. MacKenzie JD, Siddiqi F, Babb JS, Bagley LJ, Mannon LJ, et al. Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative analysis. *AJNR Am J Neuroradiol*. 2002; 23:1509–1515. [PubMed: 12372740]
56. Maxwell WL, MacKinnon MA, Stewart JE, Graham DI. Stereology of cerebral cortex after traumatic brain injury matched to the Glasgow outcome score. *Brain*. 2010; 133:139–160. [PubMed: 19897544]
57. Blatter DD, Bigler ED, Gale SD, Johnson SC, Anderson CV, et al. MR based brain and cerebrospinal fluid measurement after traumatic brain injury: correlation with neuropsychological outcome. *Am. J. Neuroradiol*. 1997; 18:1–10. [PubMed: 9010514]
58. Bigler ED, Maxwell WL. Neuroimaging and neuropathology of TBI. *NeuroRehabilitation*. 2011; 28:63–74. [PubMed: 21447905]

59. Liu Y, Spulber G, Lehtimäki KK, Kononen M, Hallikainen I, et al. Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment. *Neurobiol Aging*. 2011; 32:1558–1571. [PubMed: 19913331]
60. Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, et al. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. *J Neurol Neurosurg Psychiatry*. 2002; 72:742–746. [PubMed: 12023417]
61. Medina D, DeToledo-Morrell L, Urresta F, Gabrieli JD, Moseley M, et al. White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. *Neurobiol Aging*. 2006; 27:663–672. [PubMed: 16005548]
62. Naggara O, Oppenheim C, Rieu D, Raoux N, Rodrigo S, et al. Diffusion tensor imaging in early Alzheimer's disease. *Psychiatry Res*. 2006; 146:243–249. [PubMed: 16520023]
63. Stricker NH, Schweinsburg BC, Delano-Wood L, Wierenga CE, Bangen KJ, et al. Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. *Neuroimage*. 2009; 45:10–16. [PubMed: 19100839]
64. Xie S, Xiao JX, Gong GL, Zang YF, Wang YH, et al. Voxel-based detection of white matter abnormalities in mild Alzheimer disease. *Neurology*. 2006; 66:1845–1849. [PubMed: 16801648]
65. Zhang Y, Schuff N, Jahng GH, Bayne W, Mori S, et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. *Neurology*. 2007; 68:13–19. [PubMed: 17200485]
66. Stahl R, Dietrich O, Teipel SJ, Hampel H, Reiser MF, et al. White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. *Radiology*. 2007; 243:483–492. [PubMed: 17456872]
67. Sexton CE, Kalu UG, Filippini N, Mackay CE, Ebmeier KP. A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. *Neurobiol Aging*. 2011; 32:2322e5–2322e18. [PubMed: 20619504]
68. Cubon VA, Putukian M. A diffusion tensor imaging study on the white matter skeleton in individuals with sports-related concussion. *Journal of Neurotrauma*. 2011; 28:189–201. [PubMed: 21083414]
69. Lipton ML, Gellella E, Lo C, Gold T, Ardekani BA, et al. Multifocal white matter ultrastructural abnormalities in mild traumatic brain injury with cognitive disability: a voxel-wise analysis in diffusion tensor imaging. *J Neurotrauma*. 2008; 25:1335–1342. [PubMed: 19061376]
70. Inglese M, Makani S, Johnson G, Cohen BA, Silver JA, et al. Diffuse axonal injury in mild traumatic brain injury: a diffusion tensor imaging study. *J Neurosurg*. 2005; 103:298–303. [PubMed: 16175860]
71. Kraus MF, Susmaras T, Caughlin BP, Walker CJ, Sweeney JA, et al. White matter integrity and cognition in chronic traumatic brain injury: a diffusion tensor imaging study. *Brain*. 2007; 130:2508–2519. [PubMed: 17872928]
72. Davenport ND, Lim KO, Armstrong MT, Sponheim SR. Diffuse and spatially variable white matter disruptions are associated with blast-related mild traumatic brain injury. *Neuroimage*. 2012; 59:2017–2024. [PubMed: 22040736]
73. Little DM, Kraus MF, Joseph J, Geary EK, Susmaras T, et al. Thalamic integrity underlies executive dysfunction in traumatic brain injury. *Neurology*. 2010; 74:558–564. [PubMed: 20089945]
74. Ljungqvist J, Nilsson D, Ljungberg M, Sorbo A, Esbjörnsson E, et al. Longitudinal study of the diffusion tensor imaging properties of the corpus callosum in acute and chronic diffuse axonal injury. *Brain Inj*. 2011; 25:370–378. [PubMed: 21355671]
75. Miles L, Grossman RI, Johnson G, Babb JS, Diller L, et al. Short-term DTI predictors of cognitive dysfunction in mild traumatic brain injury. *Brain Inj*. 2008; 22:115–122. [PubMed: 18240040]
76. Niogi SN, Mukherjee P, Ghajar J, Johnson C, Kolster RA, et al. Extent of microstructural white matter injury in postconcussive syndrome correlates with impaired cognitive reaction time: a 3T diffusion tensor imaging study of mild traumatic brain injury. *AJNR Am J Neuroradiol*. 2008; 29:967–973. [PubMed: 18272556]

77. Salmond CH, Menon DK, Chatfield DA, Williams GB, Pena A, et al. Diffusion tensor imaging in chronic head injury survivors: correlations with learning and memory indices. *Neuroimage*. 2006; 29:117–124. [PubMed: 16084738]
78. Matsushita M, Hosoda K, Naitoh Y, Yamashita H, Kohmura E. Utility of diffusion tensor imaging in the acute stage of mild to moderate traumatic brain injury for detecting white matter lesions and predicting long-term cognitive function in adults. *J Neurosurg*. 2011; 115:130–139. [PubMed: 21417709]
79. Messe A, Caplain S, Paradot G, Garrigue D, Mineo JF, et al. Diffusion tensor imaging and white matter lesions at the subacute stage in mild traumatic brain injury with persistent neurobehavioral impairment. *Hum Brain Mapp*. 2011; 32:999–1011. [PubMed: 20669166]
80. Arfanakis K, Houghton VM, Carew JD, Rogers BP, Dempsey RJ, et al. Diffusion tensor MR imaging in diffuse axonal injury. *AJNR Am J Neuroradiol*. 2002; 23:794–802. [PubMed: 12006280]
81. Kumar R, Gupta RK, Husain M, Chaudhry C, Srivastava A, et al. Comparative evaluation of corpus callosum DTI metrics in acute mild and moderate traumatic brain injury: its correlation with neuropsychometric tests. *Brain Inj*. 2009; 23:675–685. [PubMed: 19557571]
82. Singh M, Jeong J, Hwang D, Sungkarat W, Gruen P. Novel diffusion tensor imaging methodology to detect and quantify injured regions and affected brain pathways in traumatic brain injury. *Magn Reson Imaging*. 2010; 28:22–40. [PubMed: 19608369]
83. Lange RT, Iverson GL, Brubacher JR, Madler B, Heran MK. Diffusion tensor imaging findings are not strongly associated with postconcussional disorder 2 months following mild traumatic brain injury. *J Head Trauma Rehabil*. 2012; 27:188–198. [PubMed: 21642855]
84. Smits M, Houston GC, Dippel DW, Wielopolski PA, Vernooij MW, et al. Microstructural brain injury in post-concussion syndrome after minor head injury. *Neuroradiology*. 2011; 53:553–563. [PubMed: 20924757]
85. Henry LC, Tremblay J, Tremblay S, Lee A, Brun C, et al. Acute and chronic changes in diffusivity measures after sports concussion. *J Neurotrauma*. 2011; 28:2049–2059. [PubMed: 21864134]
86. Mayer AR, Ling J, Mannell MV, Gasparovic C, Phillips JP, et al. A prospective diffusion tensor imaging study in mild traumatic brain injury. *Neurology*. 2010; 74:643–650. [PubMed: 20089939]
87. Mantini D, Perrucci MG, Del Gratta C, Romani GL, Corbetta M. Electrophysiological signatures of resting state networks in the human brain. *Proc Natl Acad Sci USA*. 2007; 104:13170–13175. [PubMed: 17670949]
88. De Luca M, Beckmann CF, De Stefano N, Matthews PM, Smith SM. fMRI resting state networks define distinct modes of long-distance interactions in the human brain. *Neuroimage*. 2006; 29:1359–1367. [PubMed: 16260155]
89. Cole DM, Smith SM, Beckmann CF. Advances and pitfalls in the analysis and interpretation of resting-state FMRI data. *Front Syst Neurosci*. 2010; 4:8. [PubMed: 20407579]
90. Raichle ME, Mintun MA. Brain work and brain imaging. *Annu Rev Neurosci*. 2006; 29:449–476. [PubMed: 16776593]
91. Greicius MD, Kiviniemi V, Tervonen O, Vainionpaa V, Alahuhta S, et al. Persistent default-mode network connectivity during light sedation. *Hum Brain Mapp*. 2008; 29:839–847. [PubMed: 18219620]
92. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, et al. A default mode of brain function. *Proc Natl Acad Sci USA*. 2001; 98:676–682. [PubMed: 11209064]
93. van den Heuvel MP, Hulshoff Pol HE. Exploring the brain network: a review on resting-state fMRI functional connectivity. *Eur Neuropsychopharmacol*. 2010; 20:519–534. [PubMed: 20471808]
94. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. *Ann N Y Acad Sci*. 2008; 1124:1–38. [PubMed: 18400922]
95. Uddin LQ, Kelly AM, Biswal BB, Castellanos FX, Milham MP. Functional connectivity of default mode network components: correlation, anticorrelation, and causality. *Hum Brain Mapp*. 2009; 30:625–637. [PubMed: 18219617]
96. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI. *Proc Natl Acad Sci USA*. 2004; 101:4637–4642. [PubMed: 15070770]

97. Rombouts SA, Barkhof F, Goekoop R, Stam CJScheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. *Hum Brain Mapp.* 2005; 26:231–239. [PubMed: 15954139]
98. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. *J Neurosci.* 2006; 26:10222–10231. [PubMed: 17021177]
99. Wang L, Zang Y, He Y, Liang M, Zhang X, et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. *Neuroimage.* 2006; 31:496–504. [PubMed: 16473024]
100. Sorg C, Riedl V, Mühlau M, Calhoun VD, Eichele T, et al. Selective changes of resting state networks in individuals at risk for Alzheimer's disease. *Proc Natl Acad Sci USA.* 2007; 104:18760–18765. [PubMed: 18003904]
101. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol.* 2004; 55:306–319. [PubMed: 14991808]
102. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. *J Neurosci.* 2005; 25:7709–7717. [PubMed: 16120771]
103. Damoiseaux JS, Prater KE, Miller BL, Greicius MD. Functional connectivity tracks clinical deterioration in Alzheimer's disease. *Neurobiol Aging.* 2012; 33:828 e819–828 e830. [PubMed: 21840627]
104. Sharp DJ, Beckmann CF, Greenwood R, Kinnunen KM, Bonnelle V, et al. Default mode network functional and structural connectivity after traumatic brain injury. *Brain.* 2011; 134:2233–2247. [PubMed: 21841202]
105. Bonnelle V, Leech R, Kinnunen KM, Ham TE, Beckmann CF, et al. Default mode network connectivity predicts sustained attention deficits after traumatic brain injury. *J Neurosci.* 2011; 31:13442–13451. [PubMed: 21940437]
106. Mayer AR, Mannell MV, Ling J, Gasparovic C, Yeo RA. Functional connectivity in mild traumatic brain injury. *Human Brain Mapping.* 2011; 32:1825–1835. [PubMed: 21259381]
107. Stevens MC, Lovejoy D, Kim J, Oakes H, Kureshi I, et al. Multiple resting state network functional connectivity abnormalities in mild traumatic brain injury. *Brain Imaging Behav.* 2012; 6:293–318. [PubMed: 22555821]
108. Tang CY, Eaves EL, Ng JC, Carpenter DM, Kanellopoulou I, et al. Brain networks for working memory and factors of intelligence assessed in males and females with fMRI and DTI. *Intelligence.* 2010; 38:293–303.
109. Herholz K. PET studies in dementia. *Ann Nucl Med.* 2003; 17:79–89. [PubMed: 12790355]
110. Frackowiak RS, Magistretti PJ, Shulman RG, Altman JS, Adams M. *Neuroenergetics: Relevance for functional brain imaging.* Strasbourg: Human Frontier Science Program. 2001
111. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. *Nucl Med Commun.* 2008; 29:193–207. [PubMed: 18349789]
112. Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. *Cerebrovasc Brain Metab Rev.* 1991; 3:297–335. [PubMed: 1772739]
113. Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, et al. FDG PET imaging in patients with pathologically verified dementia. *J Nucl Med.* 2000; 41:1920–1928. [PubMed: 11079505]
114. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. *Am J Psychiatry.* 2002; 159:738–745. [PubMed: 11986126]
115. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. *Eur J Nucl Med Mol Imaging.* 2005; 32:486–510. [PubMed: 15747152]

116. Villain N, Desgranges B, Viader F, de la Sayette V, Mezenge F, et al. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. *J Neurosci*. 2008; 28:6174–6181. [PubMed: 18550759]
117. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2009; 36:811–822. [PubMed: 19142633]
118. Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Neuroimage*. 2009; 45:1107–1116. [PubMed: 19349228]
119. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. *Ann Neurol*. 1997; 42:85–94. [PubMed: 9225689]
120. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. *Ann Neurol*. 2003; 54:343–351. [PubMed: 12953266]
121. Ikonomic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain*. 2008; 131:1630–1645. [PubMed: 18339640]
122. Mintun MA, Sacco D, Snyder AZ, Couture L, Powers WJ, Hornbeck R, et al. Distribution of glycolysis in the resting healthy human brain correlates with distribution of beta-amyloid plaques in Alzheimer's disease. *Soc. Neurosci*. 2006 Abstr: 707.6.
123. Bergsneider M, Hovda DA, Shalmon E, Kelly DF, Vespa PM, et al. Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. *J Neurosurg*. 1997; 86:241–251. [PubMed: 9010426]
124. Bergsneider M, Hovda DA, McArthur DL, Etchepare M, Huang SC, et al. Metabolic recovery following human traumatic brain injury based on FDG-PET: time course and relationship to neurological disability. *J Head Trauma Rehabil*. 2001; 16:135–148. [PubMed: 11275575]
125. Bergsneider M, Hovda DA, Lee SM, Kelly DF, McArthur DL, et al. Dissociation of cerebral glucose metabolism and level of consciousness during the period of metabolic depression following human traumatic brain injury. *J Neurotrauma*. 2000; 17:389–401. [PubMed: 10833058]
126. Nakayama N, Okumura A, Shinoda J, Nakashima T, Iwama T. Relationship between regional cerebral metabolism and consciousness disturbance in traumatic diffuse brain injury without large focal lesions: an FDG-PET study with statistical parametric mapping analysis. *J Neurol Neurosurg Psychiatry*. 2006; 77:856–862. [PubMed: 16549415]
127. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, et al. Inflammation after trauma: microglial activation and traumatic brain injury. *Ann Neurol*. 2011; 70:374–383. [PubMed: 21710619]
128. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, et al. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. *Brain*. 2013; 136:28–42. [PubMed: 23365092]
129. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. *Neuron*. 2007; 53:337–351. [PubMed: 17270732]
130. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, et al. Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease. *Neurodegener Dis*. 2010; 7:38–41. [PubMed: 20160456]
131. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. *Nat Rev Neurol*. 2010; 6:193–201. [PubMed: 20234358]
132. Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. *J Neural Transm*. 2010; 117:971–979. [PubMed: 20571837]
133. Brettschneider J, Toledo JB, Van Deerlin VM, Elman L, McCluskey L, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. *PLoS One*. 2012; 7:e39216. [PubMed: 22720079]

134. Brettschneider J, Libon DJ, Toledo JB, Xie SX, McCluskey L, et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. *Acta Neuropathol.* 2012; 123:395–407. [PubMed: 22210083]
135. Small GW, Kepe V, Siddarth P, Ercoli LM, Merrill DA, et al. PET scanning of brain tau in retired national football league players: preliminary findings. *Am J Geriatr Psychiatry.* 2013; 21:138–144. [PubMed: 23343487]
136. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. *J Neuropathol Exp Neurol.* 2009; 68:709–735. [PubMed: 19535999]
137. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurol.* 2009; 8:464–474. [PubMed: 19375664]
138. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. *Mov Disord.* 2008; 23:183–189. [PubMed: 17987654]
139. Martland HS. Punch Drunk. *JAMA.* 1928; 91:1103–1107.
140. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, et al. Head trauma preceding PD: a case-control study. *Neurology.* 2003; 60:1610–1615. [PubMed: 12771250]
141. Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. *Occup Environ Med.* 2007; 64:666–672. [PubMed: 17332139]
142. Factor SA, Weiner WJ. Prior history of head trauma in Parkinson's disease. *Mov Disord.* 1991; 6:225–229. [PubMed: 1922127]
143. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, et al. Head injury and Parkinson's disease risk in twins. *Ann Neurol.* 2006; 60:65–72. [PubMed: 16718702]
144. Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, et al. Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. *Neurology.* 2002; 58:79–84. [PubMed: 11781409]
145. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. *Neurology.* 1993; 43:1173–1180. [PubMed: 8170564]
146. Stern MB. Head trauma as a risk factor for Parkinson's disease. *Mov Disord.* 1991; 6:95–97. [PubMed: 2057017]
147. Taylor CA, Saint-Hilaire MH, Cupples LA, Thomas CA, Burchard AE, et al. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. *Am J Med Genet.* 1999; 88:742–749. [PubMed: 10581500]
148. Tsai CH, Lo SK, See LC, Chen HZ, Chen RS, et al. Environmental risk factors of young onset Parkinson's disease: a case-control study. *Clin Neurol Neurosurg.* 2002; 104:328–333. [PubMed: 12140099]
149. Wright JM, Keller-Byrne J. Environmental determinants of Parkinson's disease. *Arch Environ Occup Health.* 2005; 60:32–38. [PubMed: 16961006]
150. Baldereschi M, Di Carlo A, Vanni P, Ghetti A, Carbonin P, et al. Lifestyle-related risk factors for Parkinson's disease: a population-based study. *Acta Neurol Scand.* 2003; 108:239–244. [PubMed: 12956856]
151. De Michele G, Filla A, Volpe G, De Marco V, Gogliettino A, et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. *Mov Disord.* 1996; 11:17–23. [PubMed: 8771062]
152. Duzcan F, Zencir M, Ozdemir F, Cetin GO, Bagci H, et al. Familial influence on parkinsonism in a rural area of Turkey (Kizilcaboluk-Denizli): a community-based case-control study. *Mov Disord.* 2003; 18:799–804. [PubMed: 12815659]
153. Hofman A, Collette HJ, Bartelds AI. Incidence and risk factors of Parkinson's disease in The Netherlands. *Neuroepidemiology.* 1989; 8:296–299. [PubMed: 2586699]
154. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. *Mov Disord.* 1999; 14:928–939. [PubMed: 10584666]
155. Martyn CN, Osmond C. Parkinson's disease and the environment in early life. *J Neurol Sci.* 1995; 132:201–206. [PubMed: 8543949]

156. McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, et al. The epidemiology of Parkinson's disease in an Australian population. *Neuroepidemiology*. 1998; 17:310–317. [PubMed: 9778597]
157. Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA. Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain. *Acta Neurol Scand*. 1994; 89:164–170. [PubMed: 8030397]
158. Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. *Neurology*. 1996; 46:1275–1284. [PubMed: 8628466]
159. Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, et al. A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. *Neurotoxicology*. 1998; 19:709–712. [PubMed: 9745932]
160. Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. *J Neurol Sci*. 2003; 216:163–167. [PubMed: 14607318]
161. Werneck AL, Alvarenga H. Genetics, drugs and environmental factors in Parkinson's disease. A case-control study. *Arq Neuropsiquiatr*. 1999; 57:347–355. [PubMed: 10450337]
162. Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. *Acta Neurol Scand*. 2002; 105:77–82. [PubMed: 11903115]
163. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. *Eur J Epidemiol*. 2011; 26(Suppl 1):S1–S58. [PubMed: 21626386]
164. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. *Neuron*. 2003; 40:453–456. [PubMed: 14642269]
165. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. *Parkinsonism Relat Disord*. 2004; 10(Suppl 1):S3–S7. [PubMed: 15109580]
166. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 1988; 51:745–752. [PubMed: 2841426]
167. Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, et al. Head injury, alpha-synuclein Rep1, and Parkinson's disease. *Ann Neurol*. 2012; 71:40–48. [PubMed: 22275250]
168. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. *Ann Neurol*. 2008; 63:743–750. [PubMed: 18571778]
169. Goldstein DS, Sewell L. Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. *Parkinsonism Relat Disord*. 2009; 15:516–520. [PubMed: 19201246]
170. Piao YS, Mori F, Hayashi S, Tanji K, Yoshimoto M, et al. Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies. *Acta Neuropathol*. 2003; 105:403–409. [PubMed: 12624794]
171. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. *J Neurol*. 2005; 252:753–764. [PubMed: 15999234]
172. Mondello S, Buki A, Italiano D, Jeromin A. alpha-Synuclein in CSF of patients with severe traumatic brain injury. *Neurology*. 2013; 80:1662–1668. [PubMed: 23553480]
173. Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, et al. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. *Neurodegener Dis*. 2010; 7:300–318. [PubMed: 20616565]
174. Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. *Brain*. 2002; 125(Pt 4):789–800. [PubMed: 11912112]
175. Schulz JB, Skalej M, Wedekind D, Luft AR, Abele M, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. *Ann Neurol*. 1999; 45:65–74. [PubMed: 9894879]

176. Huber SJ, Shuttleworth EC, Christy JA, Chakeres DW, Curtin A, et al. Magnetic resonance imaging in dementia of Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 1989; 52:1221–1227. [PubMed: 2592966]
177. Ramirez-Ruiz B, Marti MJ, Tolosa E, Bartres-Faz D, Summerfield C, et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. *J Neurol*. 2005; 252:1345–1352. [PubMed: 15995795]
178. Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder GM, et al. Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. *J Neural Transm*. 2001; 108:571–580. [PubMed: 11459077]
179. Ibarretxe-Bilbao N, Junque C, Marti MJ, Valldeoriola F, Vendrell P, et al. Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: A voxel-based diffusion tensor imaging study. *Mov Disord*. 2010; 25:1888–1894. [PubMed: 20669268]
180. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. *Brain*. 2004; 127:791–800. [PubMed: 14749292]
181. Summerfield C, Junque C, Tolosa E, Salgado-Pineda P, Gomez-Anson B, et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. *Arch Neurol*. 2005; 62:281–285. [PubMed: 15710857]
182. Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. *Brain*. 2002; 125:789–800. [PubMed: 11912112]
183. Laakso MP, Partanen K, Riekkinen P, Lehtovirta M, Helkala EL, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. *Neurology*. 1996; 46:678–681. [PubMed: 8618666]
184. Menke RA, Scholz J, Miller KL, Deoni S, Jbabdi S, et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. *Neuroimage*. 2009; 47:435–441. [PubMed: 19447183]
185. Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. *Neurology*. 2002; 58:575–580. [PubMed: 11865135]
186. Schocke MF, Seppi K, Esterhammer R, Kremser C, Mair KJ, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. *Neuroimage*. 2004; 21:1443–1451. [PubMed: 15050569]
187. Blain CR, Barker GJ, Jarosz JM, Coyle NA, Landau S, et al. Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. *Neurology*. 2006; 67:2199–2205. [PubMed: 17190944]
188. Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. *Neurology*. 2003; 60:922–927. [PubMed: 12654954]
189. Seppi K, Schocke MF, Donnemiller E, Esterhammer R, Kremser C, et al. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. *Mov Disord*. 2004; 19:1438–1445. [PubMed: 15390073]
190. Chan LL, Rumpel H, Yap K, Lee E, Loo HV, et al. Case control study of diffusion tensor imaging in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2007; 78:1383–1386. [PubMed: 17615165]
191. Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. *Neurology*. 2009; 72:1378–1384. [PubMed: 19129507]
192. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. *J Neurol Neurosurg Psychiatry*. 2004; 75:481–484. [PubMed: 14966170]

193. Gattellaro G, Minati L, Grisoli M, Mariani C, Carella F, et al. White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. *AJNR Am J Neuroradiol.* 2009; 30:1222–1226. [PubMed: 19342541]
194. Du G, Lewis MM, Styner M, Shaffer ML, Sen S, et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. *Mov Disord.* 2011; 26:1627–1632. [PubMed: 21618607]
195. Rolheiser TM, Fulton HG, Good KP, Fisk JD, McKelvey JR, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. *J Neurol.* 2011; 258:1254–1260. [PubMed: 21287185]
196. Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. *Brain.* 2010; 133:3423–3433. [PubMed: 20736190]
197. Zhan W, Kang GA, Glass GA, Zhang Y, Shirley C, et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. *Mov Disord.* 2012; 27:90–97. [PubMed: 21850668]
198. Karagulle Kendi AT, Lehericy S, Luciana M, Ugurbil K, Tuite P. Altered diffusion in the frontal lobe in Parkinson disease. *AJNR Am J Neuroradiol.* 2008; 29:501–505. [PubMed: 18202242]
199. Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, et al. White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. *Neuroimage.* 2012; 62:1675–1684. [PubMed: 22713671]
200. Zhang K, Yu C, Zhang Y, Wu X, Zhu C, et al. Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease. *Eur J Radiol.* 2011; 77:269–273. [PubMed: 19692193]
201. Zhang Y, Schuff N, Du AT, Rosen HJ, Kramer JH, et al. White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. *Brain.* 2009; 132:2579–2592. [PubMed: 19439421]
202. Ibarretxe-Bilbao N, Junque C, Marti MJ, Valldeoriola F, Vendrell P, et al. Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: A voxel-based diffusion tensor imaging study. *Mov Disord.* 2010; 25:1888–1894. [PubMed: 20669268]
203. Drevets WC. Orbitofrontal cortex function and structure in depression. *Ann N Y Acad Sci.* 2007; 1121:499–527. [PubMed: 17872395]
204. Aoki Y, Inokuchi R, Gunshin M, Yahagi N, Suwa H. Diffusion tensor imaging studies of mild traumatic brain injury: a meta-analysis. *J Neurol Neurosurg Psychiatry.* 2012; 83:870–876. [PubMed: 22797288]
205. Hulkower MB, Poliak DB, Rosenbaum SB, Zimmerman ME, Lipton ML. A Decade of DTI in Traumatic Brain Injury: 10 Years and 100 Articles Later. *AJNR Am J Neuroradiol.* 2013; 34:2064–2074. [PubMed: 23306011]
206. Geary EK, Kraus MF, Pliskin NH, Little DM. Verbal learning differences in chronic mild traumatic brain injury. *J Int Neuropsychol Soc.* 2010; 16:506–516. [PubMed: 20188015]
207. Helmich RC, Derikx LC, Bakker M, Scheeringa R, Bloem BR, et al. Spatial remapping of cortico-striatal connectivity in Parkinson's disease. *Cereb Cortex.* 2010; 20:1175–1186. [PubMed: 19710357]
208. Brooks DJ, Piccini P. Imaging in Parkinson's disease: the role of monoamines in behavior. *Biol Psychiatry.* 2006; 59:908–918. [PubMed: 16581032]
209. Rivlin-Etzion M, Marmor O, Heimer G, Raz A, Nini A, et al. Basal ganglia oscillations and pathophysiology of movement disorders. *Curr Opin Neurobiol.* 2006; 16:629–637. [PubMed: 17084615]
210. van Eimeren T, Siebner HR. An update on functional neuroimaging of parkinsonism and dystonia. *Curr Opin Neurol.* 2006; 19:412–419. [PubMed: 16914982]
211. Wu T, Wang L, Chen Y, Zhao C, Li K, et al. Changes of functional connectivity of the motor network in the resting state in Parkinson's disease. *Neurosci Lett.* 2009; 460:6–10. [PubMed: 19463891]

212. Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ. Resting state functional connectivity of the striatum in Parkinson's disease. *Brain*. 2012; 135:3699–3711. [PubMed: 23195207]
213. Seibert TM, Murphy EA, Kaestner EJ, Brewer JB. Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. *Radiology*. 2012; 263:226–234. [PubMed: 22371611]
214. Luo C, Song W, Chen Q, Zheng Z, Chen K, et al. Reduced functional connectivity in early-stage drug-naïve Parkinson's disease: a resting-state fMRI study. *Neurobiol Aging*. 2014; 35:431–441. [PubMed: 24074808]
215. Palmer SJ, Eigenraam L, Hoque T, McCaig RG, Troiano A, et al. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease. *Neuroscience*. 2009; 158:693–704. [PubMed: 18722512]
216. Wu T, Wang L, Chen Y, Zhao C, Li K, et al. Changes of functional connectivity of the motor network in the resting state in Parkinson's disease. *Neurosci Lett*. 2009; 460:6–10. [PubMed: 19463891]
217. Delaveau P, Salgado-Pineda P, Fossati P, Witjas T, Azulay JP, et al. Dopaminergic modulation of the default mode network in Parkinson's disease. *Eur Neuropsychopharmacol*. 2010; 20:784–792. [PubMed: 20674286]
218. Esposito F, Tessitore A, Giordano A, De Micco R, Paccone A, et al. Rhythm-specific modulation of the sensorimotor network in drug-naïve patients with Parkinson's disease by levodopa. *Brain*. 2013; 136:710–725. [PubMed: 23423673]
219. Baudrexel S, Witte T, Seifried C, von Wegner F, Beissner F, et al. Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease. *Neuroimage*. 2011; 55:1728–1738. [PubMed: 21255661]
220. Kasahara M, Menon DK, Salmond CH, Outtrim JG, Taylor Tavares JV, et al. Altered functional connectivity in the motor network after traumatic brain injury. *Neurology*. 2010; 75:168–176. [PubMed: 20625170]
221. Brooks DJ, Pavese N. Imaging biomarkers in Parkinson's disease. *Prog Neurobiol*. 2011; 95:614–628. [PubMed: 21896306]
222. Huang C, Ravdin LD, Nirenberg MJ, Piboolnurak P, Severt L, et al. Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study. *Dement Geriatr Cogn Disord*. 2013; 35:183–196. [PubMed: 23445555]
223. Berding G, Odin P, Brooks DJ, Nikkha G, Matthies C, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. *Mov Disord*. 2001; 16:1014–1022. [PubMed: 11748732]
224. Huang C, Tang C, Feigin A, Lesser M, Ma Y, et al. Changes in network activity with the progression of Parkinson's disease. *Brain*. 2007; 130:1834–1846. [PubMed: 17470495]
225. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. *J Clin Invest*. 2005; 115:1449–1457. [PubMed: 15931380]
226. Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, et al. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. *Amyotroph Lateral Scler Frontotemporal Degener*. 2013; 14(Suppl 1):5–18. [PubMed: 23678876]
227. Belli S, Vanacore N. Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease? *Eur J Epidemiol*. 2005; 20:237–242. [PubMed: 15921041]
228. Chio A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. *Brain*. 2005; 128:472–476. [PubMed: 15634730]
229. Pupillo E, Messina P, Logroscino G, Zoccolella S, Chio A, et al. Trauma and amyotrophic lateral sclerosis: a case-control study from a population-based registry. *Eur J Neurol*. 2012; 19:1509–1517. [PubMed: 22537412]
230. Woods AH. Trauma as a cause of amyotrophic lateral sclerosis. *JAMA* LVI. 1911:1876–1877.

231. Schmidt S, Kwee LC, Allen KD, Oddone EZ. Association of ALS with head injury, cigarette smoking and APOE genotypes. *J Neurol Sci.* 2010; 291:22–29. [PubMed: 20129626]
232. Williams DB, Annegers JF, Kokmen E, O'Brien PC, Kurland LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. *Neurology.* 1991; 41:1554–1557. [PubMed: 1922795]
233. Turner MR, Abisgold J, Yeates DG, Talbot K, Goldacre MJ. Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS. *J Neurol Sci.* 2010; 288:45–48. [PubMed: 19878957]
234. Qureshi MM, Hayden D, Urbinelli L, Ferrante K, Newhall K, et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). *Amyotroph Lateral Scler.* 2006; 7:173–182. [PubMed: 16963407]
235. Murros K, Fogelholm R. Amyotrophic lateral sclerosis in Middle-Finland: an epidemiological study. *Acta Neurol Scand.* 1983; 67:41–47. [PubMed: 6601351]
236. Douaud G, Filippini N, Knight S, Talbot K, Turner MR. Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. *Brain.* 2011; 134:3470–3479. [PubMed: 22075069]
237. Leigh PN, Anderton BH, Dodson A, Gallo JM, Swash M, et al. Ubiquitin deposits in anterior horn cells in motor neurone disease. *Neurosci Lett.* 1988; 93:197–203. [PubMed: 2853844]
238. Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. *Acta Neuropathol.* 2012; 124:339–352. [PubMed: 22903397]
239. McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. *J Neuropathol Exp Neurol.* 2010; 69:918–929. [PubMed: 20720505]
240. Loane DJ, Byrnes KR. Role of microglia in neurotrauma. *Neurotherapeutics.* 2010; 7:366–377. [PubMed: 20880501]
241. Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. *Exp Neurol.* 2013; 246:35–43. [PubMed: 22285252]
242. Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. *Brain Behav Immun.* 2012; 26:1191–1201. [PubMed: 22728326]
243. Kassubek J, Unrath A, Huppertz HJ, Lule D, Ethofer T, et al. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. *Amyotroph Lateral Scler Other Motor Neuron Disord.* 2005; 6:213–220. [PubMed: 16319024]
244. Chang JL, Lomen-Hoerth C, Murphy J, Henry RG, Kramer JH, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. *Neurology.* 2005; 65:75–80. [PubMed: 16009889]
245. Mezzapesa DM, Ceccarelli A, Dicuonzo F, Carella A, De Caro MF, et al. Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. *AJNR Am J Neuroradiol.* 2007; 28:255–259. [PubMed: 17296989]
246. Verstraete E, Veldink JH, Mandl RC, van den Berg LH, van den Heuvel MP. Impaired structural motor connectome in amyotrophic lateral sclerosis. *PLoS One.* 2011; 6:e24239. [PubMed: 21912680]
247. Roccatagliata L, Bonzano L, Mancardi G, Canepa C, Caponnetto C. Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler.* 2009; 10:47–52. [PubMed: 18622772]
248. Iwata NK, Aoki S, Okabe S, Arai N, Terao Y, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. *Neurology.* 2008; 70:528–532. [PubMed: 18268244]
249. Nelles M, Block W, Traber F, Wullner U, Schild HH, et al. Combined 3T diffusion tensor tractography and 1H-MR spectroscopy in motor neuron disease. *AJNR Am J Neuroradiol.* 2008; 29:1708–1714. [PubMed: 18701582]
250. Sage CA, Van Hecke W, Peeters R, Sijbers J, Robberecht W, et al. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis: revisited. *Hum Brain Mapp.* 2009; 30:3657–3675. [PubMed: 19404990]

251. Wong JC, Concha L, Beaulieu C, Johnston W, Allen PS, et al. Spatial profiling of the corticospinal tract in amyotrophic lateral sclerosis using diffusion tensor imaging. *J Neuroimaging*. 2007; 17:234–240. [PubMed: 17608909]
252. Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, et al. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. *Neurology*. 2010; 75:1645–1652. [PubMed: 21041787]
253. Jelsone-Swain LM, Fling BW, Seidler RD, Hovatter R, Gruis K, et al. Reduced Interhemispheric Functional Connectivity in the Motor Cortex during Rest in Limb-Onset Amyotrophic Lateral Sclerosis. *Front Syst Neurosci*. 2010; 4:158. [PubMed: 21228916]
254. Mohammadi B, Kollewé K, Samii A, Krampfl K, Dengler R, et al. Changes of resting state brain networks in amyotrophic lateral sclerosis. *Exp Neurol*. 2009; 217:147–153. [PubMed: 19416664]
255. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. *Neurobiol Dis*. 2004; 15:601–609. [PubMed: 15056468]
256. Millsbaugh JA. Dementia Pugilistica. *US Naval Med Bulletin*. 1937; 35:297–361.
257. Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. *Psychol Med*. 1973; 3:270–303. [PubMed: 4729191]
258. Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, et al. Chronic traumatic encephalopathy in a National Football League player. *Neurosurgery*. 2005; 57:128–134. [PubMed: 15987548]
259. Omalu BI, DeKosky ST, Hamilton RL, Minster RL, Kamboh MI, et al. Chronic traumatic encephalopathy in a national football league player: part II. *Neurosurgery*. 2006; 59:1086–1092. [PubMed: 17143242]
260. Omalu B, Hammers JL, Bailes J, Hamilton RL, Kamboh MI, et al. Chronic traumatic encephalopathy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide. *Neurosurg Focus*. 2011; 31:E3. [PubMed: 22044102]
261. Roberts GW, Allsop D, Bruton C. The occult aftermath of boxing. *J Neurol Neurosurg Psychiatry*. 1990; 53:373–378. [PubMed: 2191084]
262. McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, et al. The spectrum of disease in chronic traumatic encephalopathy. *Brain*. 2013; 136:43–64. [PubMed: 23208308]
263. Hazrati LN, Tartaglia MC, Diamandis P, Davis KD, Green RE, et al. Absence of chronic traumatic encephalopathy in retired football players with multiple concussions and neurological symptomatology. *Front Hum Neurosci*. 2013; 7:222. [PubMed: 23745112]
264. Lakhan SE, Kirchgessner A. Chronic traumatic encephalopathy: the dangers of getting "dinged". *Springerplus*. 2012; 1:2. [PubMed: 23984220]
265. Baugh CM, Stamm JM, Riley DO, Gavett BE, Shenton ME, et al. Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma. *Brain Imaging Behav*. 2012; 6:244–254. [PubMed: 22552850]
266. Gavett BE, Stern RA, McKee AC. Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. *Clin Sports Med*. 2011; 30:179–188. [PubMed: 21074091]
267. Stern RA, Riley DO, Daneshvar DH, Nowinski CJ, Cantu RC, et al. Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy. *PM R*. 2011; 3:S460–S467. [PubMed: 22035690]
268. Crisco JJ, Fiore R, Beckwith JG, Chu JJ, Brolinson PG, et al. Frequency and location of head impact exposures in individual collegiate football players. *J Athl Train*. 2010; 45:549–559. [PubMed: 21062178]
269. Greenwald RM, Gwin JT, Chu JJ, Crisco JJ. Head impact severity measures for evaluating mild traumatic brain injury risk exposure. *Neurosurgery*. 2008; 62:789–798. [PubMed: 18496184]
270. Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? *Nat Rev Neurol*. 2013; 9:211–221. [PubMed: 23458973]
271. Orrison WW, Hanson EH, Alamo T, Watson D, Sharma M, et al. Traumatic brain injury: a review and high-field MRI findings in 100 unarmed combatants using a literature-based checklist approach. *J Neurotrauma*. 2009; 26:689–701. [PubMed: 19335205]

272. Davenport ND, Lim KO, Armstrong MT, Sponheim SR. Diffuse and spatially variable white matter disruptions are associated with blast-related mild traumatic brain injury. *Neuroimage*. 2012; 59:2017–2024. [PubMed: 22040736]
273. Bazarian JJ, Zhu T, Blyth B, Borrino A, Zhong J. Subject-specific changes in brain white matter on diffusion tensor imaging after sports-related concussion. *Magn Reson Imaging*. 2012; 30:171–180. [PubMed: 22079073]
274. Provenzano FA, Jordan B, Tikofsky RS, Saxena C, Van Heertum RL, et al. F-18 FDG PET imaging of chronic traumatic brain injury in boxers: a statistical parametric analysis. *Nucl Med Commun*. 2010; 31:952–957. [PubMed: 20717065]
275. Peskind ER, Petrie EC, Cross DJ, Pagulayan K, McCraw K, et al. Cerebrocerebellar hypometabolism associated with repetitive blast exposure mild traumatic brain injury in 12 Iraq war Veterans with persistent post-concussive symptoms. *Neuroimage*. 2011; 54(Suppl 1):S76–S82. [PubMed: 20385245]
276. Hampshire A, MacDonald A, Owen AM. Hypoconnectivity and hyperfrontality in retired American football players. *Sci Rep*. 2013; 3:2972. [PubMed: 24135857]
277. Talavage TM, Nauman EA, Breedlove EL, Yoruk U, Dye AE, et al. Functionally-Detected Cognitive Impairment in High School Football Players Without Clinically-Diagnosed Concussion. *J Neurotrauma*. 2013
278. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, et al. Head injury and the risk of AD in the MIRAGE study. *Neurology*. 2000; 54:1316–1323. [PubMed: 10746604]
279. Fang F, Chen H, Feldman AL, Kamel F, Ye W, et al. Head injury and Parkinson's disease: a population-based study. *Mov Disord*. 2012; 27:1632–1635. [PubMed: 23143933]
280. Lee PC, Bordelon Y, Bronstein J, Ritz B. Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. *Neurology*. 2012; 79:2061–2066. [PubMed: 23150532]
281. Harris MA, Shen H, Marion SA, Tsui JK, Teschke K. Head injuries and Parkinson's disease in a case-control study. *Occup Environ Med*. 2013; 70:839–844. [PubMed: 24142978]
282. McCrory P, Meeuwisse WH, Aubry M, Cantu RC, Dvorak J, et al. Consensus statement on concussion in sport: the 4th International Conference on Concussion in Sport, Zurich, November 2012. *J Athl Train*. 2013; 48:554–575. [PubMed: 23855364]
283. McCrory P, Meeuwisse W, Johnston K, Dvorak J, Aubry M, et al. Consensus statement on concussion in sport - the Third International Conference on Concussion in Sport held in Zurich, November 2008. *Phys Sportsmed*. 2009; 37:141–159. [PubMed: 20048521]
284. McCrory P, Johnston K, Meeuwisse W, Aubry M, Cantu R, et al. Summary and agreement statement of the 2nd International Conference on Concussion in Sport, Prague 2004. *Br J Sports Med*. 2005; 39:196–204. [PubMed: 15793085]
285. Aubry M, Cantu R, Dvorak J, Graf-Baumann T, Johnston K, et al. Summary and agreement statement of the First International Conference on Concussion in Sport, Vienna 2001. Recommendations for the improvement of safety and health of athletes who may suffer concussive injuries. *Br J Sports Med*. 2002; 36:6–10. [PubMed: 11867482]
286. Practice parameter: the management of concussion in sports (summary statement). Report of the Quality Standards Subcommittee. *Neurology*. 1997; 48:581–585. [PubMed: 9065530]
287. Center for Disease Control and Prevention. Traumatic Brain Injury. 2013. Retrieved from <http://www.cdc.gov/concussion/sports/>
288. Institute of Medicine (IOM) and National Research Council (NRC). Sports-related concussions in youth: Improving the science, changing the culture. Washington, DC: The National Academies Press; 2013.
289. Schwab KA, Ivins B, Cramer G, Johnson W, Sluss-Tiller M, et al. Screening for traumatic brain injury in troops returning from deployment in Afghanistan and Iraq: initial investigation of the usefulness of a short screening tool for traumatic brain injury. *J Head Trauma Rehabil*. 2007; 22:377–389. [PubMed: 18025970]
290. Delaney JS, Lacroix VJ, Leclerc S, Johnston KM. Concussions among university football and soccer players. *Clin J Sport Med*. 2002; 12:331–338. [PubMed: 12466687]

291. McCrea M, Hammeke T, Olsen G, Leo P, Guskiewicz K. Unreported concussion in high school football players: implications for prevention. *Clin J Sport Med.* 2004; 14:13–17. [PubMed: 14712161]
292. Bey T, Ostick B. Second impact syndrome. *West J Emerg Med.* 2009; 10:6–10. [PubMed: 19561758]
293. Hootman JM, Dick R, Agel J. Epidemiology of collegiate injuries for 15 sports: summary and recommendations for injury prevention initiatives. *J Athl Train.* 2007; 42:311–319. [PubMed: 17710181]

Table 1

Varying features of NDs

	AD	PD	ALS	CTE
Clinical signs & symptoms	Dementia; progressive cognitive impairments memory loss	<ul style="list-style-type: none"> - Motor symptoms resting tremor, rigidity, bradykinesia, impaired balance - Comorbid symptoms: depression, MCI, olfaction dysfunction 	<ul style="list-style-type: none"> - Progressive weakness, atrophy, and spasticity of muscle caused by motor neuron death 	<ul style="list-style-type: none"> - Affective disturbances; irritability, depression, aggression - Social instability, memory loss, cognitive decline - Motor impairments
Pathology/Abnormal proteins	<ul style="list-style-type: none"> - Aβ - Tau NFTs (uniformly distributed, less dense than CTE) 	<ul style="list-style-type: none"> - Dopaminergic lesions in substantia nigra (SN) - Lewy body accumulation, specifically α-synuclein 	<ul style="list-style-type: none"> - TDP 43 - Increased microglial activation 	<ul style="list-style-type: none"> - Aβ (less consistent than AD) - Tau NFTs (randomly distributed dense clusters, depths of sulci, superficial layers) - α-synuclein and TDP-43
Gross structural findings	<ul style="list-style-type: none"> - Global atrophy - Increased VBR - Atrophy to hippocampus, amygdala, & uncus 	<ul style="list-style-type: none"> - Regional atrophy in hippocampus, amygdala, orbitofrontal cortex, SN, & anterior cingulate 	<ul style="list-style-type: none"> - Trend of global cerebral atrophy 	<ul style="list-style-type: none"> - Global cerebral atrophy and various subcortical structures - Increased VBR - cavum septum pellucidum - septal fenestrations - thinning of CC - pallor of SN
Microstructural WM injuries	<ul style="list-style-type: none"> - Global WM abnormalities. Specifically uncinate, ILF, SLF, fornix, cingulum, hippocampus & CC 	<ul style="list-style-type: none"> - WM impairments in SN, CC, hippocampus, SLF, ILF, uncinate, cingulum, external capsule, corticospinal tract, & cerebellum 	<ul style="list-style-type: none"> - Marked damage to corticospinal tract - WM impairments in primary motor cortex, SMA, basal ganglia, precuneus, and CC 	<ul style="list-style-type: none"> - Unknown - Populations with frequent exposure to head trauma generally have damaged microstructural WM as a result of DAI
Functional abnormalities	<ul style="list-style-type: none"> - Hyperactive DMN in early AD, but quickly 	<ul style="list-style-type: none"> - Neurochemical imbalance 	<ul style="list-style-type: none"> - Impaired FC in sensorimotor, premotor, 	<ul style="list-style-type: none"> - Unknown - Populations with frequent

	AD	PD	ALS	CTE
	<p>diminishes as AD progresses</p> <ul style="list-style-type: none"> - Hypometabolism throughout temporo-parietal cortex. Specifically in the PCC, thalamus, hippocampus & frontal cortex 	<ul style="list-style-type: none"> - disrupted connectivity in corticostriatal loops - increased FC in motor cortex and STN - increased CMRgl in STN, GP, motor cortex - Decreased CMRgl in prefrontal and inferior parietal regions 	<p>prefrontal, and thalamic regions</p> <ul style="list-style-type: none"> - Decreased FC between left and right primary motor cortices - Decreased DMN 	<p>exposure to head trauma reportedly exhibit decreased CMRgl in PCC, parieto-occipito lobes and cerebellum. Altered FC in the DLPFC and frontal gyri are also reported in this population</p>

Table 2

Methods and findings of previous epidemiological studies

Reference	Disease	Case Definition for TBI	Methodology	OR	Relevant Findings
Fratiglioni et al 1993 ²⁷	AD	LOC	Interview an "informant" of the patient	.4	
Mayeux et al 1995 ³⁰	AD	LOC	Interview	1.5	OR: 10.5 for e4 carriers
Guo et al 2000 ²⁷⁸	AD	LOC or medical attention	Structured questionnaire	4.6	OR: 9.9 for TBI with LOC
Plassman et al 2000 ³²	AD	Medical record of LOC, post-traumatic amnesia or skull fracture occurring during military service	Military health records	2.16	
Chen et al 2007 ¹⁹	ALS	Injury requiring medical attention	Interview	1.4	OR:3.1 for head injury in 10 years leading up to onset of ALS
Schmidt et al 2010 ²³¹	ALS	LOC or medical care	Telephone interview	1.26	OR: 1.88 for TBI occurring at older age (>29)
Turner et al 2010 ²³³	ALS	N/A	Reviewed data from Oxford Record Linkage Data	1.5	
Stern et al 1991 ¹⁴⁶	PD	Head trauma severe enough to cause vertigo, dizziness, blurred vision, seizure or convulsion, transient memory loss, personality change or paralysis	Structured interview	2.9	
Martyn and Osmond 1995 ¹⁵⁵	PD	LOC or hospital admission	Standardized questionnaire	.6	
Kuopio et al 1999 ¹⁵⁴	PD	N/A	Interview	.89	OR:1.99 for multiple TBI OR:1.37 for TBI with LOC
Taylor et al 1999 ¹⁴⁷	PD	Head trauma severe enough to cause LOC, blurred/double vision, dizziness, seizures, or memory loss	Structured interview	5.09	
Tsai et al 2002 ¹⁴⁸	PD	Head trauma severe enough to cause vertigo or dizziness, LOC, post-traumatic amnesia, personality changes, seizures or paralysis	Structured Questionnaire	9.27	OR: 4.5 for young onset PD (< 40 years of age) compared to normal PD patients
Zorzon et al 2002 ¹⁶²	PD	LOC	Structured interview	1.6	
Baldereschi et al 2003 ¹⁵⁰	PD	LOC	Standardized questionnaire interview	.85	
Bower et al 2003 ¹⁴⁰	PD	LOC, posttraumatic amnesia, neurologic signs of Brain Injury, or Skull fracture with documented medical record	Medical history screened by nurse and confirmed by neurologist	4.3	OR:11 for TBI with LOC TBI with Hospitalization: 8
Goldman et al 2006 ¹⁴³	PD	Amnesia or LOC following head injury	Phone interview	3.6	OR:4.3 for multiple TBI OR:4.1 for TBI resulting in hospitalization
Dick et al 2007 ¹⁴¹	PD	"Ever being knocked unconscious"	Standardized questionnaire interview	1.35	OR: 2.53 for multiple TBIs with LOC
Fang et al 2012 ²⁷⁹	PD	Hospitalization	Medical records	1.94	

Reference	Disease	Case Definition for TBI	Methodology	OR	Relevant Findings
Lee et al 2012 ²⁸⁰	PD	LOC > 5 minutes in duration	Interview	2	
Goldman et al 2012 ¹⁶⁷	PD	Affirmative response to “Have you ever had a head injury where you lost consciousness or were diagnosed with a concussion by a doctor?”	Computer assisted phone interview	1.3	OR: 3.5 for Long Rep1 allele carries with TBI history
Harris et al 2013 ²⁸¹	PD	Injury requiring physician attention	Standardized questionnaire interview	2.08	OR: 2.64 for TBI with LOC